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Abstract 
 
 Luminescent semiconductor quantum dots (QDs) are extensively researched for use in 
biological applications. They have unique optical and physical properties that make them 
excellent candidates to replace conventional organic dyes for cellular labeling, multiplexing, 
nucleic acid detection, and as generalized probes. The primary focus of this dissertation was to 
utilize quantum dots for improvement in immunoassays. Specifically, atherosclerosis biomarkers 
were detected simultaneously in an effort to demonstrate advances in early detection diagnostics.  
 Quantum dot-antibody bioconjugates were prepared by encapsulation into mesoporous 
silica and functionalized with thiol and amine groups to enable bioconjugation. Functionalization 
of the mesoporous silica quantum dot composites facilitated biocompatibility for use with 
biological buffers in immunoassays. These bioconjugates were used in a sandwich immunoassay 
to detect atherosclerosis biomarkers IL-15 and MCP-1. Sandwich assays employ capture 
antibodies immobilized onto a well plate to bind as much of the antigen as possible. The capture 
antibodies increased binding by at least 4 times the amount of antigen bound to the surface of a 
direct detection assay. The sandwich immunoassay was able to detect 1 pg/mL of IL-15 and 50 
pg/mL of MCP-1 biomarkers. 
 Human serum albumin nanoparticles (HSAPs) were synthesized via a desolvation and 
crosslinking method. Human serum albumin is a versatile protein being used in a variety of 
applications. Quantum dots were loaded into HSAPs as potential detection probes for 
immunoassays. Efficient loading was not achieved, and the assay was unable to improve current 
detection limits. 
xiii 
 
 Controlled release studies were explored using HSAPs loaded with superparamagnetic 
iron oxide nanoparticles and a fluorescent drug analog. Exposure to a magnetic field resulted in 
degradation of the HSAPs. The fluorophore was released and measured to examine how cancer 
drugs might be controlled through a magnetic field. Gold nanorods and an anticancer drug, 
Sorafenib, were also encapsulated into HSAPs for treatment of renal cell carcinoma in vivo. 
Laser irradiation treatment combined with Sorafenib resulted in 100% tumor necrosis and total 
elimination of any viable tumor present. HSAPs have demonstrated remarkable potential as drug 
delivery nanocarriers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Quantum dots, fluorescence, silica, immunoassay, multiplexing, atherosclerosis, 
human serum albumin, drug delivery, biomarkers, biosensor
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Chapter 1 
Introduction 
 
1.1 Objectives and Aims 
 
 The main objective of this research was to develop and optimize a sensitive multiplex 
bioanalytical assay utilizing luminescent semiconductor quantum dots to detect the presence of 
atherosclerosis biomarkers. Quantum dots have a wide array of advantages over conventional 
organic dye molecules used for analysis methods. Encapsulating quantum dots into mesoporous 
silica provides a multitude of barcodes for detection assays. Human serum albumin nanoparticles 
have also shown potential as a multifunctional analytical diagnostic and therapeutic tool. 
Employing quantum dots into human serum albumin nanoparticles can further enhance 
barcoding agents for theranostic applications. Additionally, the versatility of human serum 
albumin nanoparticles was explored as multimodal nanocarriers for targeted drug delivery 
utilizing combined methods of controlled release with nanoparticle materials. The specific aims 
of this research were 1) synthesis of water-soluble quantum dot loaded mesoporous silica 
composite particles as biosensors, 2) preparation of human serum albumin nanoparticles loaded 
with quantum dots, 3) multiplex detection of atherosclerosis biomarkers using a fluorescence-
based immunoassay, and 4) exploration of targeted drug delivery using human serum albumin 
nanoparticles. 
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1.2 Significance 
 
Early disease detection and prevention is critical across all arenas of healthcare 
worldwide. Rapid and effective diagnosis of many diseases could lead to earlier treatment 
assessments, improve prognosis, and increase lifetimes. Diagnostic tests and early screenings are 
only reliable when the tests are sensitive, precise, and specific.
1
 New biomarkers are constantly 
being discovered for different cancers and diseases, and the need for consistent and accurate 
means of detection is increasing.
2-3
 This research mostly focuses on detection of atherosclerosis 
biomarkers. Atherosclerosis is a main component of cardiovascular disease (CVD), which is the 
leading cause of death for men and women globally.
4-6
 Earlier detection of atherosclerosis is 
critical in order to reduce the astounding financial costs related to treatment and assessment as 
well as to reduce the likelihood of heart attack or stroke over an individual’s lifetime.7-8 
Bioanalytical immunoassays are one of the main tools for measuring the presence of elevated 
levels of biomarkers in biological fluids such as blood serum and urine.
9-10
 Immunoassays 
depend on specific, inherent antibody-antigen binding to indicate the presence of a given marker, 
however, many key factors affect the sensitivity and reproducibility of the assays.
9, 11-12
 One 
component, in particular, is the detection reagent or probe used that produces the signal 
specifying the amount of analyte present.
10
 Many bioassays rely on fluorophores to measure the 
amount of a given protein because fluorescent molecules can be detected with high specificity, 
but they can be limited chemically and physically.
9, 13-18
 Photobleaching, low fluorescence 
quantum yield, and broad emission spectra are a few of the limitations of conventional organic 
dyes.
13, 18
 Luminescent semiconductor quantum dots (QDs) have advantages over organic dyes 
and have emerged as reliable alternatives.
2, 17, 19-21
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 This research primarily focused on exploiting the unique properties of semiconductor 
QDs to produce a simple, rapid, and reliable immunoassay capable of detecting multiple analytes 
at once while improving current detection limits. Encapsulating QDs into mesoporous silica 
enhances their brightness and provides easy surface functionalization for bioconjugation.
22-28
 
QDs were also loaded into human serum albumin nanoparticles (HSAPs) to develop a new 
bioprobe with potential use as a detection agent in bioassays or to enhance other fluorescently 
labeled albumin probes currently used for cell tracking and imaging tools.
29-30
 Moreover, HSAPs 
were further explored to examine their multimodal functionality as targeted and controlled drug 
release agents. Encapsulating superparamagnetic iron oxide nanoparticles with a fluorescent drug 
analog provides insight on how a drug would be released from HSAPs via magnetic 
hyperthermia.
31-32
 Loading gold nanoparticles into HSAPs for degradation via laser irradiation 
shows definite promise for controlled release of anticancer drugs directly at tumor sites.
33-35
 
1.3 Fluorescence 
 
1.3.1 The Fluorescence Process 
 Fluorescence is the emission of light by a substance due to absorption of a photon or 
other electromagnetic radiation.
36
 It is the result of a three-stage process: excitation, excited-state 
lifetime, and emission; this process is best illustrated by the Jablonksi diagram (Figure 1.1). The 
Jablonksi diagram depicts the processes that occur between absorption and emission. 
Fluorophores are typically polyaromatic hydrocarbons or heterocycles that can reach an excited 
state upon absorption of a photon and then emit light energy. The light energy emitted is at a 
lower energy than the photon absorbed due to vibrational relaxation.  
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Figure 1.1 Jablonski Diagram. 
 
During excitation, the fluorophore absorbs a photon usually from an incandescent lamp 
or laser, and an electron moves to an excited electronic state (S1 or S2). The excited state lasts for 
about 10
-15 
s, and during this time the fluorophore interacts with its molecular environment and 
can undergo conformational changes. Vibrational relaxation occurs and the electron moves to the 
ground level of the S1 state, and some energy is lost as heat during the process. From here the 
electron can relax back to the ground state (S0) and emit a photon of a lower energy and longer 
wavelength than the absorbed photon. This is the phenomenon of fluorescence. The electron can 
also relax back to the ground state through internal conversion, which is non-radiative, and a 
photon is not emitted, however, energy is lost through heat. If the electron in the S1 state 
transitions to the triplet state (T1), intersystem crossing occurs. Here, the electron can either relax 
to the S0 ground state and emit a photon as phosphorescence, or it can go back to the S1 state and 
then to the S0 ground state emitting a photon as delayed fluorescence. Photons emitting via 
phosphorescence will have an even lower energy and longer wavelength than fluorescence. An 
electron can also travel from T1 to S0 in a non-radiative form not emitting a photon, but losing 
energy as heat. Fluorescence quantum yield is the ratio of the number of photons emitted relative 
5 
 
to the number of photons absorbed and is a measure of the extent to which the different 
processes may occur. 
Fluorescence emission occurs when an excited electron relaxes back to the ground state 
and emits a photon. The energy is lower than that of the absorbed photon, and the difference in 
energy or wavelength (hυex – hυem) is called the Stokes shift. The Stokes shift is important to 
fluorescence techniques because it allows emission to be detected against a low background. 
1.3.2 Fluorescence Spectroscopy  
 Fluorescence emission can be analyzed through several different detection systems. 
Fluorescence spectrofluorometers and microplate readers are common instrumentation utilized 
for detection. Most fluorescence instruments have four basic items: 1) a light source, 2) a sample 
holder, 3) wavelength filters to isolate excitation photons and emission photons, and 4) a detector 
to read emission photons and produce a visual output of analysis.
37
 Fluorescence spectroscopy 
measurements performed in this work were measured primarily by a SpectraMax M2 microplate 
reader (Molecular Devices, Inc). This plate reader contains a Xenon flash lamp source and a 
photmultiplier (R-3896) detector. There is a built in excitation monochromator and emission 
monochromator that allows for detection of absorbance and fluorescence at multiple 
wavelengths. The light source is irradiated to the excitation monochromator allowing only 
certain wavelengths to pass through. The excited light passes through 1 mm fiber optic bundles 
to the microplate port where the light is directed to a focusing oval mirror. Incident light enters 
the sample from the top of the microplate, and the reflected light travels to the emission 
monochromator and photomultiplier tube prior for processing.  
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1.3.3 Digital Fluorescence Microscopy 
 Fluorescence microscopy is a technique for viewing and detecting fluorescence or 
phosphorescence in a substance. The microscope combines the magnifying properties of an 
optical light microscope with fluorescence technology allowing excitation and emission 
detection of the sample. Images are acquired based entirely on the fluorescence emission 
properties of the sample. This is particularly useful for live cell imaging within tissues, and 
proteins that are stained or exhibit a natural fluorescence can be imaged and tracked. An inverted 
fluorescence microscope is typically used for imaging. The components of the microscope are 
similar to that of a light microscope, but fluorescence microscopes include a powerful light 
source such as a xenon or mercury arc lamp that can emit light from UV-IR wavelengths. Filter 
cubes are another difference from traditional light microscopes; they are composed of an 
excitation filter, a dichroic mirror, and an emission filter (Figure 1.2). Light leaves the arc lamp 
and is directed through an excitation filter that selects the excitation wavelength. This light is 
reflected toward the sample by a dichroic mirror that only reflects light at the desired excitation 
wavelength. The light passes through to the objective and is focused onto the sample. The 
sample gives off its own fluorescence emission that passes back through the objective and is 
magnified. Epifluorescence is when the emission and excitation light pass through the same 
objective and can reduce the signal-to-noise ratio. The emission light passes through the dichroic 
mirror and through an emission bandpass filter. The bandpass filter only allows certain 
wavelengths to pass through thereby reducing the background, and the filtered light is sent to a 
detector such as a charge coupled device (CCD) camera where the image can be acquired 
digitally. The filtered emission light can also be directed to a spectrograph which can display the 
fluorescence emission spectrum of the sample.  The fluorescent sample determines the excitation 
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and emission wavelengths used in the filter cube, and multiple combinations of filter cubes can 
be assembled for any given fluorescent sample type.  
 
 
Figure 1.2 Illustration of the light path through a filter cube of an inverted fluorescence 
microscope. 
 
1.4 Quantum Dots 
 
1.4.1 Structural Properties  
 Quantum dots (QDs) are luminescent semiconductor nanocrystalline particles with 
unique chemical, structural, and photophysical properties.
38-41
 They are composed of elements 
from groups II-IV (CdSe, CdS, CdTe, ZnS, ZnO, ZnSe), III-V (InP, InAs, GaP, GaN, GaAs), and 
(PbS, PbSe, PbTe) of the periodic table.
38, 40, 42-44
 QDs average 2-10 nm in diameter and can 
contain hundreds to thousands of atoms.
17, 21, 38
 They approach the size of the exciton Bohr 
radius; the average distance in an electron-hole pair is confined in all three dimensions.
38, 45
 
Because both electrons and holes are confined to a small region, the mode of recombination is 
limited.
46
 QDs have characteristics in between bulk and discrete semiconductors; they differ 
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from bulk materials in that they are characterized by discrete atomic-like states.
47
 Bulk 
semiconductors have continuous energy levels with a fixed bandgap energy, but the bandgap 
energy of QDs is determined by its radius. QDs experience the quantum confinement effect, 
which is why they have discrete energy levels with finite separation between them (Figure 1.3).
48
 
The addition or subtraction of a few atoms can alter the boundaries of the bandgap. Quantum 
confinement causes increased stress on the exciton resulting in increased energy of the emitted 
photon. Smaller QDs have less room for exciton separation and more energy is required to form 
the exciton so photons will be emitted at lower wavelengths. Adjusting the size of the bandgap 
changes emission frequency, and changes in surface geometry can affect the bandgap energy. 
These factors allow control over the output wavelength of QD emission. 
 
Figure 1.3 Illustration of quantum dot size due to the quantum confinement effect. 
1.4.2 Optical Properties  
 The quantum confinement effect is essentially responsible for the unique optical 
properties exhibited by QDs that make them advantageous over organic fluorophores. When an 
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electron in the valence band is excited by photon absorption and moves to the conduction band, a 
hole is left in the valence band. When the electron relaxes back to the valence band, light is 
emitted as fluorescence. QDs have a broad absorption spectrum with narrow emission peaks, and 
relative to other common fluorophores, QDs are highly photostable. They have high emission 
quantum yield, a large molar extinction coefficient and are exceptionally bright. QDs also have a 
long fluorescence lifetime as well as a large Stokes shift and size dependent tunability. The 
surface of the QDs influences photoluminescence because of trap states that cause nonradiative 
electron transitions resulting in low quantum yield. Trap states usually occur due to dangling 
bonds or vacancies at the surface. Coating QDs, also known as surface passivation, with a shell 
of a higher bandgap semiconductor raises the quantum yield by reducing these effects. Zinc 
sulfide is commonly used as a coating shell because it enhances quantum yield, chemical 
stability, and photostability of the QDs. 
1.4.3 Synthesis of Quantum Dots 
 QDs are synthesized through various physical or chemical methods.
46
 Physical processes 
include high-energy input through molecular beam epitaxy and metal organic chemical vapor 
deposition.
38
 More recently, however, chemical methods are typically used such as high 
temperature particle growth on solid substrates or by low energy input colloidal chemical 
precipitation.
40
 Colloidal semiconductor synthesis is the most successful method in terms of 
quality and monodispersity. The system is based on the pyrolysis of organometallic precursors in 
hot coordinating solvents.
38
 Changing the temperature, concentrations, time, and ligand 
molecules precisely controls size tuning of colloidal QDs.
49
 The most widely used and 
synthesized QDs are CdSe because it has tunable absorption energy throughout the UV-Vis-NIR 
spectrum and its precursors are inexpensive and readily available.
13, 17-18, 21, 50-51
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 Synthesis of CdE (E = S, Se, Te) was first published by Murray et al. from MIT in 1993; 
they reacted dimethylcadmium Cd(CH3)2 in trioctylphosphine (TOP) with a solution of 
trioctylphosphine selenide (TOPSe) at high temperatures.
52
 Eventually, the procedure was 
modified by Peng et al by replacing Cd(CH3)2 with CdO, Cd(Ac)2, and CdCO3, and these 
cadmium precursors are typically used today.
53-54
 The mechanism for colloidal nanocrystal 
growth has been proposed to proceed from nucleation resulting from rapid injection of 
precursors into a hot coordinating solvent.
38, 52-53, 55
 The reagents undergo thermal decomposition 
and there is a supersaturation of monomers present. Monomers are added to the QD nuclei, and 
once the concentration is depleted, further growth proceeds by Ostwald ripening.
38
 The QD core 
can have low quantum yield due to surface defects, vacancies, and dangling bonds on the 
surface.
56
 When the excited electron or hole is trapped due to defects low quantum yield can 
result from nonradiative recombination. A shell of a higher bandgap semiconductor material is 
often added to overcome these defects and protect the QD core. ZnS is most ofted added to CdSe 
core QDs, and the ZnS shell reduces QD toxicity, improves quantum yield, and enhances 
photostability.  
1.4.4 Bioconjugation of Quantum Dots 
 Inorganic quantum dots are synthesized in organic solvents, which is not suitable for 
biological applications. For QDs to be used as fluorescent labels they need to be soluble in 
aqueous solvents which requires either a surface ligand exchange or encapsulation in amphiphilic 
media for bioconjugation. Exchanging the trioctylphosphine oxide (TOPO) capping ligand for 
16-mercaptohexadecanoic acid (MHDA) enables water solubility of the QDs; however, there is 
often a decrease in quantum yield and brightness after the ligand exchange.
57-58
 The ligands bind 
to the ZnS shell through thiol (-SH) groups on one end through metal affinity coordination while 
11 
 
the other enables hydrophilicity. Other ligands used to replace TOPO include dihydrolipoic acid 
(DHLA), dithiothreitol (DTT), mercaptoacetic acid (MAA), and 11-mercaptoundecanoic acid 
(MUA).
59-62
 The thiol bond to the ZnS shell is not strong enough, so QD encapsulation is a more 
appropriate method for water solubility.     
 Doping QDs into porous or mesoporous polystyrene and silica particles has shown great 
retention of luminescent properties.
28, 63-64
 Polystyrene-encapsulated QDs are prepared through 
an emulsion polymerization method.
65-66
 Polystyrene beads are dissolved in an organic solution 
causing them to swell and enlarge their pores. The QDs penetrate the pores and adsorb to the 
hydrophobic walls. Upon removal of the solvent, the pores contract, and the QDs remain inside 
of the polystyrene beads.
67
 Silica encapsulation has also been shown to increase the brightness of 
QDs of a single probe by encapsulating thousands of QDs into one silica particle.
28, 58
 Silica 
growth on the QD surface is possible through the Stöber synthesis method.
27, 68
 This is a one-step 
method that does not utilize toxic solvents.
69
 Tetraethyl orthosilicate (TEOS) condenses in 
ethanol/water mixtures at room temperature.
58, 70-71
 Multiple QDs of different sizes and emission 
wavelengths can be incorporated into the silica pores and remain stable due to strong 
hydrophobic interactions.
28
  
 The main bioconjugation methods for attachment to QDs are covalent modification, 
direct attachment, and electrostatic interactions.
13, 72-73
 Covalent modifications involve 
biomolecules attached to functional groups on the QD ligand surface. Amine (-NH2), thiol (-SH), 
and carboxyl (-COOH) groups all attach to QDs via covalent modifications. Direct attachment to 
QDs includes metal-affinity coordination to Zn atoms as well as dative thiol bonding. Proteins 
can also bind to QDs through electrostatic interactions. Quantum dot bioconjugates enable them 
for use in a multitude of applications.   
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1.4.5 Applications of Quantum Dots 
 The unique tunable properties of QDs make them useful in a wide variety of applications. 
Quantum computing, solar cells, LEDs, televisions, and diode lasers are a few of the applications 
currently under investigation for enhancement with QDs.
38-39, 46
 There is ongoing research to 
replace incandescent light bulbs with red, green, and blue QDs.  
 QDs were first described in a biological context in 1998 by Nie and Alivisatos.
59, 74
 
Inorganic QDs are limited for use in in vivo applications, especially CdSe QDs, but they are 
widely utilized for in vitro biological applications. QDs are often used as biosensors for 
immunoassays, generalized probes, nucleic acid detection, and fluorescence resonance energy 
transfer (FRET).
13-14, 75-80
 QDs have also been used for cellular labeling and imaging, and they 
have increased photoluminescence over conventional organic dyes.
16, 44, 81-82
 The greatest 
potential of quantum dot antibody bioconjugates for biosensing is multiplexing.
13, 83
 
Multiplexing is the simultaneous detection of multiple analytes in an immunoassay.
9, 80
 QD-
bioconjugates are constantly improving the sensitivity of clinical applications.
2, 11, 84
 
1.5 Human Serum Albumin 
 
 Human serum albumin (HSA) is the most abundant blood plasma protein comprising 
about 50% of the total protein present.
85
 It has extraordinary ligand binding capabilities that 
make it excellent for many bioapplications.
86
 HSA has a molecular weight of 65 kDa and 
contains 585 amino acids including 35 cysteine residues that form 17 disulfide bridges with one 
free thiol, and it also has one fluorescent tryptophan.
85, 87
 HSA is naturally biocompatible, 
biodegradable, and non-toxic.
86, 88-90
 The large amount of charged amino acids provide easy 
surface functionalization capabilities.
86
 HSA molecules are able to pass freely throughout the 
body and can pass through the blood brain barrier.
91-92
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 HSA molecules can form dimers and aggregate together for nanoparticle preparation.
86
 
Human serum albumin nanoparticles (HSAPs) are typically prepared through an alcoholic 
desolvation method.
88, 93-96
 The alcohols unfold or denature the tertiary structure of the albumin, 
and aggregates naturally coacervate or come together through electrostatic and hydrophobic 
interactions.
97-98
 A crosslinking agent such as glutaraldehyde then binds amine groups of lysine 
and arginine amino acids to one another forming albumin nanoparticles.
85, 90, 99
 
 The diameter of HSAPs is dependent on experimental conditions, and modification of the 
different parameters gives control over the nanoparticle size.
94
 The rate at which ethanol is added 
to initiate desolvation affects the particle size and polydispersity. Adding ethanol at about 1 
mL/min creates monodisperse HSAPs that average 200 nm in diameter.
88
 Furthermore, the pH 
prior to desolvation also regulates particle size. For HSAPs averaging 200 nm, the optimal pH is 
7. Adjusting the pH to 8.2 decreases particle size, and significantly lowering the pH causes 
aggregation of initial aqueous albumin solution.
88, 98
  
 HSAPs have extraordinary potential for use in a wide range of bioapplications.
85
 They 
show promise particularly as vehicles for controlled release and targeted drug delivery, and they 
exhibit multimodal functionality.
100
 As nanocarriers, HSAPs can transport toxic and insoluble 
drugs throughout the body directly to tumor sites effectively improving current chemotherapeutic 
techniques.
91, 101-103
 HSAPs covalently encapsulate and conjugate drugs with high loading 
efficiency for transport.
102, 104
 Loading other metallic, organic, or inorganic materials with the 
chemotherapeutic drug allows for controlled release.
33, 105-106
 Nanoparticle degradation and 
release of the drugs can be facilitated by magnetic nanoparticles or gold nanoparticles through 
exposure to a magnetic field or laser irradiation, respectively.
33, 35, 105-106
 Specifically directing 
14 
 
HSAPs to tumor sites also spares exposure of toxic chemotherapeutic agents to neighboring 
healthy cells.
89, 103, 107-108
  
1.6 Immunoassay Development 
 
 Many methods of protein detection are available and widely researched including: flow 
cytometry, western blots, immunoprecipitation, and immunohistochemistry. The best method, 
however, for quantifying the amount of a protein present is through a bioanalytical assay. 
Immunoassays are analytical tools for quantifying molecules based on selectivity and specificity 
of antigens and antibodies.
9
 They were first developed in the 1950s by Rosalyn Yalow and 
Solomon Berson who investigated radioisotope tracings to measure biological substances in 
human blood.
109
 The main types of immunoassays are: 1) competitive, 2) antigen-down, and 3) 
sandwich.
9
 Competitive binding assays are based upon competition of a labeled and unlabeled 
antigen for a limited number of binding sites on an antibody. A known amount of labeled, 
unbound antigen is added, and it is measured by its ability to compete with the unlabeled antigen. 
It gets blocked from binding to the antibody. The more analyte present in the sample, the more 
the labeled antigen is blocked from binding so the amount of labeled, unbound antigen is 
proportional to the amount of analyte present in the sample.
110
 Antigen-down assays involve 
binding an antigen to a solid surface for binding to antibodies present in a sample. Another 
labeled secondary antibody is added that binds to the antibodies in the sample. The signal from 
the labeled secondary antibody is proportional to the amount of primary antibody present.
80
  
Sandwich assays are the most robust and sensitive.
9, 13
 They utilize a primary antibody and a 
secondary antibody to each bind to an antigen (Figure 1.4). The primary antibody is also known 
as the capture antibody. Monoclonal antibodies are often used as the primary antibody because 
they bind to one particular epitope of an antigen.
11
 This gives the best chances for positioning the 
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antigens in the same orientation on a well plate. After the antigen is added, a labeled, secondary 
detection antibody is added. This antibody is usually polyclonal and can bind to multiple 
epitopes on a given antigen, thereby increasing the antigen-antibody binding so that as much of 
the antigen as possible can be detected.
12, 21, 111
 
 
Schematic 1.1 Schematic representation of a fluorescence sandwich immunoassay. 
 
Selection of the detection label for the antibody is a critical factor in improving sensitivity of the 
immunoassay.
9
 Examples include radioactive isotopes, DNA reporters, and chemiluminescent 
tags.
80, 112
 The most popular labels are enzymes such as horseradish peroxidase and alkaline 
phosphatase. Enzyme labels are used in enzyme-linked immunosorbent assays (ELISAs), and 
they are currently the most commercially available assay type.
9
 In a sandwich ELISA, a capture 
antibody is bound to the surface, nonspecific binding sites are blocked, and the antigen is added 
for capture by the primary antibody. Another antibody is added forming the sandwich, and it 
binds specifically to the antigen. ELISAs require an additional secondary antibody that is linked 
to an enzyme; this antibody is used to bind to the antibody already bound to the antigen.
110
 A 
16 
 
chemical is added that converts the enzyme into a fluorescent or electrochemical signal.
113
 The 
antigen can be quantified by measuring the absorbance or fluorescence of the signal.
113-114
 
Typically, the enzymatic reaction is short-term, and the signal must be measured immediately. 
Other limitations include false positives and negatives as well as altered enzymatic activity due 
to assay constituents. Replacing the label from an enzyme to quantum dots eliminates the need 
for a third antibody and reduces the chance for nonspecific binding.
13, 20, 30, 79, 115-119
  
1.7 Atherosclerosis 
 
 Cardiovascular disease (CVD) is the leading cause of death worldwide for men and 
women accounting for about 1 in 3 deaths.
8
 Atherosclerosis is a condition where the vascular 
arteries harden and increase in thickness, and it is a main contributor to CVD.
5-6
 An 
atherosclerotic plaque can lead to heart attack or stroke if it ruptures. Typically, cholesterol and 
other fatty materials or atheroma accumulate in an artery and lead to blockages that restrict blood 
flow, which can form blood clots.
7
 Atherosclerosis is a chronic disease, and it is not unusual for 
plaque formation to begin during childhood. The formation of an atherosclerotic plaque takes 
place over a series of steps. Low-density lipoproteins (LDL) transport cholesterol from the liver 
to the cells, and when it is oxidized it can cause damage to an artery wall.
4, 7
 Macrophages or 
white blood cells are then sent to the artery wall to repair and absorb the oxidized-LDL. This 
reaction forms foam cells, and accumulation of foam cells forms plaque in the artery wall.
5
 Two 
types of plaque can form: stable or unstable. Stable plaque formation is usually not harmful; the 
artery wall will increase in diameter and blood flow will not be restricted. They are 
asymptomatic and contain smooth muscle cells. Unstable plaques, however, have a tendency to 
rupture and increase the incidence of blood clots.
7
 They are composed of macrophages and foam 
cells. When blood flow is restricted due to blockages, the risk for heart attack or stroke rises. 
17 
 
Additionally, when plaques harden or calcify blood flow is also restricted, blood pressure is 
increased, and risk for clots rise.
120
 
 Monitoring the progression of atherosclerosis could greatly improve prognosis and 
reduce the risk for plaque rupture. Detection for atherosclerosis is in dire need of enhancement in 
order to lower the number of fatal cardiovascular events. Unfortunately, diagnosis of 
atherosclerosis occurs typically after plaque formation has occurred. Angiograms, stress tests, 
cholesterol tests, X-rays, computed tomography (CT) scans, and electrocardiograms (EKG) are 
often ordered to examine abnormal behavior in the vascular system.
8
 Imaging techniques are 
beneficial, but they are used to search for atheroma and assess the condition of the artery walls. 
Angiograms can provide information on the lipid-rich plaques in an artery, but again, this is not 
ideal for early detection or monitoring of the progression of atherosclerosis. CT scans are 
effective at imaging calcification, but there must be substantial plaque present for imaging. 
Recently, clinical intravascular ultrasounds have been able to detect and measure atheroma, but it 
is invasive, extremely costly, and not widely utilized.  
 Several biomarkers have recently been identified as indicative of atherosclerotic plaques 
at various stages of plaque development from as early as the development of precursor legions to 
fatty acid streaks and complete lipid-rich plaques.
4
 Monocyte chemoattractant protein-1 (MCP-1) 
and interleukin 15 (IL-15) are two of the more recently discovered biomarkers.
121-122
 MCP-1 is a 
chemokine that rises in macrophage-rich areas of atherosclerotic plaques.
123
 Chemokines are 
released in response to signals from proinflammatory cytokines. IL-15 is a cytokine expressed in 
immune cells and atherosclerotic lesions.
124
 It is uniquely found in lipid-rich plaques in complex 
foam cells, and it stimulates T lymphocytes. High levels of IL-15 have also been found in 
18 
 
patients with coronary artery disease.
124
 Early detection of these biomarkers could lead to early 
treatment and assessment of atherosclerosis leading to improved prognosis for CVD.
7
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Chapter 2 
 
Synthesis of Water-Soluble Mesoporous Silica Quantum Dot Composite 
Particles 
 
2.1 Abstract 
 
 Quantum dots are being exploited for their unique optical and physical properties to 
enhance many bioanalytical applications. Most fluorescent biosensors are composed of organic 
fluorophores, but they are limiting in their capabilities due to photobleaching and short 
fluorescence lifetime. Quantum dots are able to enhance numerous biosensing methods by 
overcoming many of the challenges organic fluorophores face. CdSe/ZnS quantum dots were 
used specifically to develop biosensors to improve immunoassays for biomarker detection. 
Quantum dots of different sizes were efficiently loaded into mesoporous silica particles ranging 
from 3-10 µm in diameter with 32 nm pores. In addition to silica composites containing single 
emission quantum dots, quantum dots of different sizes and emission wavelengths were precisely 
loaded into single silica composite particles. A wide selection of quantum dot loaded silica 
composite particles affords biological assays the ability to detect several analytes simultaneously. 
Incorporating CdSe/ZnS quantum dots into mesoporous silica enhances their brightness and 
provides a simple means for bioconjugation strategies. 
Coupling the quantum dot mesoporous silica composites to antibodies is a key 
component for immunoassay optimization. Modifying them with amine or thiol groups allows 
for simple bioconjugation with antibodies. APTES and MPTMS were added to the quantum dot 
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silica composites to introduce amine and thiol groups, respectively. Tetraethyl orthosilicate 
(TEOS) was used to coat the SiQDs, effectively sealing the pores and preventing leakage of the 
QDs. Adding TEOS caused a shift of the emission wavelength of the SiQDs. The amount of 
TEOS added determined the change in emission wavelength. This modification allows for more 
spectral codes that can be used as biosensors without needing several different color quantum 
dots. These water soluble mesoporous silica quantum dot composites are used to develop 
immunoassays for biomarker detection. 
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2.2 Introduction 
 
 Bioanalytical assays commonly employ fluorescent probes as biosensors for detecting or 
quantitating other molecules.
1
 Biosensors are often used for immunoassays, nucleic acid 
detection, fluorescence resonance energy transfer, and cellular labeling applications.
1
 Fluorescent 
organic dyes and fluorescent proteins have been the most used as fluorophores for assays 
because of their high fluorescence intensity, but they face many photophysical challenges 
limiting their efficiency as reliable biosensors.
2
 Quantum dots (QDs) have been found to be 
useful in bioanalytical applications.
1, 3
 They have many unique spectral and optical properties 
that are advantageous over conventional organic dyes.
1-2, 4
  
Quantum dots were first identified in literature through a biological context in 1998.
5-6
 
Organic fluorophores, while highly luminescent, have a short fluorescence lifetime, small Stokes 
shift, and are largely pH dependent.
1, 7-8
 Additionally, organic dyes and proteins have narrow 
absorption windows with broad emission spectra, and they are also susceptible to photobleaching 
and self-quenching.
9-12
 Quantum dots are more robust than organic fluorophores and exhibit a 
multitude of distinct photophysical properties suitable for biosensing applications.
8, 13
 These 
properties include: a large molar extinction coefficient, high quantum yield, broad absorption 
spectrum along with narrow size-tunable photoluminescent emission, and high resistance to 
photobleaching and chemical degradation.
13-19
 QDs also have a relatively long fluorescence 
lifetime, high photstability, size-dependent tunability and large Stokes shifts.
1, 16, 20-21
 A wide 
array of biological and chemical applications has utilized their extensive properties including: 
immunoassays, FRET, DNA targeting, cellular labeling and imaging, as well as pathogen and 
toxin detection.
1-2, 11, 16, 22-23
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 Proper fluorescent labels for biosensing functionalities are bright and soluble in buffers or 
culture media.
13
 They should also be stable, biocompatible, and easily functionalized for 
bioconjugation.
1, 11, 23
 QDs are usually stored in inorganic solvents making them unsuitable as 
fluorescent labels and solubility in aqueous solvents requires either a surface ligand exchange or 
encapsulation in an amphiphilic media to allow for bioconjugation.
24-29
 CdSe/ZnS core-shell 
QDs are most commonly used for bioanalytical applications, and they typically have a 
hydrophobic trioctylphosphine oxide (TOPO) capping ligand.
30-31
 Water soluble CdSe/ZnS QDs 
can be prepared by exchanging TOPO for mercaptohexadecanoic acid (MHDA), however, these 
QDs often display a substantial decrease in brightness and quantum yield compared to TOPO-
capped QDs.
24, 26
 QD encapsulation provides a more efficient means to enhance water solubility 
while maintaining the distinct, inherent properties QDs exhibit. 
 Doping QDs into porous or mesoporous polystyrene and silica particles has shown 
excellent retention of luminescent properties making them useful for spectral encoding.
2, 4, 12, 32-33
 
Polystyrene-encapsulated QDs can be prepared through an emulsion polymerization method 
whereby polystyrene beads are dissolved in an organic solution causing them to swell and 
enlarge their pores allowing QDs to penetrate the pores and adsorb to the hydrophobic walls.
32-33
 
The pores contract upon removal of the solvent and the QDs remain inside the polystyrene beads. 
Silica encapsulation of fluorophores has shown to be a simple process that enables 
bioconjugation and increases photostability and emission quantum yield.
4, 25
 Ruthenium diimine 
complexes have been successfully incorporated into mesoporous silica particles via the Stöber 
synthesis method.
25
 The Stöber method is a one-step synthesis involving the condensation of 
tetraethyl orthosilicate (TEOS) in ethanol/water mixtures at room temperature.
25, 34
 This method 
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provides great control over the size of the resulting silica particles as well as a narrow size 
distribution and smooth morphology.
25, 35
 
2.3 Experimental Methods 
 
2.3.1 Materials and Reagents 
All chemicals were used as received without modification unless otherwise noted. Cadmium 
oxide (99.99%), lauric acid (98%), technical grade (90%) trioctylphosphine oxide (TOPO), 
technical grade (90%) hexadecylamine (HDA), technical grade (90%) trioctylphosphine (TOP), 
selenium powder (99.5%), diethyl zinc solution 1.0 M in heptane, hexamethyldisilathiane, 
methanol anhydrous (99.8%), chloroform (99.5%), tetraethyl orthosilicate (TEOS), (3-
aminopropyl)triethoxysilane (APTES), propanol, and 3-mercaptopropyltrimethoxysilane 
(MPTMS) were purchased from Sigma-Aldrich (St. Louis, MO). Mesoporous silica particles 
with 32 nm C18 modified pores were obtained from Phenomenex (Torrance, CA). Ethanol, 200-
proof, ACS/USP grade was purchased from Pharmco-AAPER (Brookfield, CT). N-
(trimethoxysilylpropyl)ethylenediaminetriacetate, trisodium salt, 35% in water was purchased 
from Gelest (Morrisville, PA). Nanopure deionized and distilled water (18.2 MΩ) purified with a 
Barnstead Nanopure system was used for all experiments. 
2.3.2 Synthesis of TOPO coated luminescent quantum dots 
TOPO coated CdSe/ZnS quantum dots were prepared using a slightly modified version of 
a method developed by Peng.
30-31
 Briefly, 12.5 mg of cadmium oxide (CdO) and 180 mg of 
lauric acid were mixed in a three-neck flask under a nitrogen atmosphere. The mixture was 
heated to 180-200 °C until the CdO fully dissolved in the lauric acid forming a clear, colorless 
solution. Once fully dissolved, 1.94 g of trioctylphosphine oxide (TOPO) and 1.94 g of 
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hexadecylamine (HDA) were added to the solution under constant stirring. The temperature was 
increased to 280 °C for 10 minutes before being cooled down slowly. Meanwhile, a solution of 
80 mg of selenium powder was dissolved in 2 mL of trioctylphosphine (TOP). This solution was 
rapidly injected into the mixture under vigorous stirring upon reaching the desired temperature 
during the cooling process. Size-tunable luminescent quantum dots are directly dependent upon 
temperature. The temperature at which the selenium component is injected determines the size of 
the quantum dots synthesized, corresponding to their emission wavelength. Typically, the 
temperature is slowly decreased from 280 °C to 180 °C. The higher the temperature upon 
injection, the larger the quantum dots will be in size.
36
 A precursor solution for a ZnS shell was 
prepared: 2 mL of TOP containing 1 mL of diethyl zinc (Zn(Et)2) and 250 µL of 
hexamethyldisilathiane ((TMS)2S). This shell was added dropwise into the solution after 
injection of the selenium. The reaction mixture was kept at 180 °C for 1 hour before cooling to 
room temperature. The resulting CdSe/ZnS quantum dots were washed 3 times with methanol by 
centrifugation at 4000 rpm for 10 minutes and resdispersed in chloroform. The quantum dots 
were stored at room temperature in the dark. 
 
Scheme 2.1 Synthesis of CdSe/ZnS Quantum Dots. 
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2.3.3 Preparation of Quantum Dot Mesoporous Silica Composite Particles (SiQDs) with 
Single and Multiple Quantum Dots at Controlled Ratios 
Preparation of mesoporous fluorescent silica microbeads were based on previously 
reported methods. Briefly, 4 mg of mesoporous silica particles averaging 3, 5, or 10 µm in 
diameter with 32 nm C18-modified pores were dispersed in 2 mL of butanol. Two hundred 
microliters of TOPO-CdSe/ZnS quantum dots were added to the solution under stirring. This 
mixture was incubated for 1 hour and washed 3 times with ethanol by centrifugation at 11,000 
rpm for 20 minutes. The fluorescent silica microbeads were visualized using an Olympus IX-71 
inverted microscope and stored at 4 °C.  
For coding of single mesoporous silica beads with multiple quantum dots, a premixed 
solution of quantum dots varying in size was prepared. Controlled ratios are prepared by varying 
the volumes of the different quantum dot solutions. The premixed solution of multiple CdSe/ZnS 
quantum dots is added rapidly to the mesoporous silica in butanol and incubated with stirring for 
1 hour followed by washing with ethanol.  
2.3.4 Synthesis of TEOS-coated Fluorescent Mesoporous Silica Beads 
TEOS coated fluorescent mesoporous silica beads were prepared by dispersing 2 mg of 
mesoporous fluorescent silica particles in 2 mL of ethanol and 500 µL of nanopure water. Upon 
stirring, 25, 50, 100, or 200 µL of tetraethyl orthosilicate (TEOS) was added dropwise. The 
mixture was incubated overnight and washed 3 times with ethanol for 20 min at 11,000 rpm. The 
resulting silica beads were resdispersed in 2 mL of ethanol and visualized using an Olympus IX-
71 inverted fluorescence microscope. They were stored at 4 °C until further use. 
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2.3.5 Amine-modified TEOS capped SiQDs 
TEOS-capped mesoporous silica beads were further modified by the addition of an amine 
group for bioconjugation. While stirring, 100 µL of (3-aminopropyl)triethoxysilane (APTES) 
was added to the TEOS-capped mesoporous silica beads. They were incubated overnight and 
washed with ethanol for 20 min at 11,000 rpm. The particles were resdispersed in nanopure 
water via ultrasonication and visualized with an Olympus IX-71 inverted fluorescence 
microscope. These particles were used immediately for bioconjugation. 
2.3.6 Thiol-modified SiQDs 
Mesoporous silica beads were also modified with a thiol group for bioconjugation. 
Quantum dot loaded mesoporous silica beads were dispersed in 1 mL of propanol and 1 mL of 
water. To this solution 100 µL of 3-mercaptopropyltrimethoxysilane (MPTMS) was added while 
stirring. This mixture incubated overnight and was washed 3 times with ethanol for 20 min at 
11,000 rpm. The thiol-capped mesoporous silica beads were resdispersed in 1 mL of water and 1 
mL of propanol and 50 µL of N-(trimethoxysilylpropyl)ethylenediaminetriacetate was added 
dropwise. The mixture stirred overnight and was washed 3 times with nanopure water. The 
resulting particles were dispersed in nanopure water and used immediately for fluorescence 
immunoassays. 
2.3.7 Fluorescence Spectroscopy Measurements 
Fluorescence emission spectra were obtained using a SpectraMax M2 spectrofluorometer 
microplate reader (Molecular Devices, Inc.) equipped with a 75 W continuous Xenon flash arc 
lamp as a light source and a photomultiplier (R-3896) detector. The excitation wavelength for all 
samples was 420 nm. Fluorescence emission was measured from 450-750 nm. 
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2.3.8 Digital Fluorescence Imaging Microscopy 
Fluorescence images were taken using a digital fluorescence imaging microscopy system 
containing an Olympus IX-71 inverted fluorescence microscope equipped with a 100 X mercury 
lamp as a light source and a high performance color charge coupled device (CCD) camera 
(Olympus DP 70). Images were obtained through 10x, 20x, 40x, and 60x microscope objectives 
with numerical aperture = 0.5. A filter cube with a 425 20 nm band-pass excitation filter, a 465 
dichroic mirror, and a 475 nm long pass emission filter was used for spectral imaging. Image 
analysis was done using DP Controller software. An exposure time of 10 ms was typically used 
for image acquisition. Fluorescence emission spectra and images of individual fluorescent silica 
microparticles in solution were taken using a digital fluorescence imaging microscopy system 
containing an Olympus IX-70 inverted fluorescence microscope coupled with a 0.300 m imaging 
triple grating monochromator/spectrograph Model SpectraPro 2300i. Spectral analysis of 
emission spectra was done using Roper Scientific software WinSpec/32. Emission spectra were 
collected using a filter cube with a 425 20 nm band-pass excitation filter, a 465 dichroic mirror, 
and a 475 nm long pass emission filter. An exposure time of 1000 ms was typically used for 
spectral acquisition. Emission spectra were taken for 20 different beads selected at random and 
averaged for analysis.  
2.3.9 Dynamic Light Scattering (DLS) Measurements 
Average particle size, zeta potential, and mobility of amine-modified fluorescent silica 
quantum dot composites were determined through dynamic light scattering. The values were 
obtained using a Mobius dynamic light scattering instrument (Wyatt Technology Corporation, 
Santa Barbara, CA) at 25 °C. Samples were dissolved in nanopure water prior to analysis. 
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2.4 Results and Discussion 
 
2.4.1 Fluorescence Emission of CdSe/ZnS Quantum Dots 
 High-quality colloidal quantum dots are synthesized through pyrolysis of organometallic 
precursors in TOPO/TOP coordinating solvents.
30
 Size-tunable luminescent QDs are directly 
dependent on temperature.
36-37
 The temperature at which the selenium component is injected 
determines the size of the quantum dots, corresponding to their emission wavelength. The higher 
the temperature upon injection, the larger the resulting diameter of the QDs.
38
 Figure 2.1 depicts 
the fluorescence emission spectra of four different CdSe/ZnS QDs solutions; the only difference 
in preparation for each was the temperature at which the selenium in TOP component was added 
to the reaction mixture.  
 
 
 
 
 
 
36 
 
 
 
Figure 2.1 Fluorescence spectra (λex = 400 nm) of CdSe/ZnS QDs emitting at (a) 475 nm, (b) 
560 nm, (c) 565 nm, and (d) 620 nm. 
 
CdSe/ZnS QDs fluoresce in the visible range, the lower the temperature at which selenium was 
added, the smaller the resulting QDs, the shorter their emission wavelength, and the bluer the 
QDs will fluoresce. The higher the temperature at which selenium is added, the longer their 
emission wavelength, and the redder the QDs will fluoresce. Blue QDs are about 2 nm in size, 
and red QDs are about 10 nm in size.  
2.4.2 Fluorescence Emission of Mesoporous Silica Beads (SiQDs) 
 Encapsulating QDs into mesoporous silica enhances their brightness and retains the 
integrity of the CdSe/ZnS core-shell structure.
39
 The mesoporous silica has 32 nm pores which 
allow the QDs to penetrate into the silica where they remain stable because of strong 
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hydrophobic interactions between the C18 hydrocarbon chain on the silica pore wall and the 
TOPO capping ligand on the surface of the CdSe/ZnS QDs (Scheme 2.2). 
 
Scheme 2.2 Schematic representation of the hydrophobic interactions between the hydrocarbon 
chain of the silica pore wall and the TOPO capping ligand on the quantum dot surface. 
 
Quantum dot fluorescence emission is directly related to size, and red QDs are the largest. These 
QDs will have a harder time competing with the smaller QDs for incorporation through the pores 
into the beads when loading multiple QDs of different sizes. Fluorescence microscopy images of 
blue, green, and red SiQDs are shown with corresponding overall emission spectra with max 
emission at λ = 480 nm, 560 nm, and 620 nm, respectively (Figure 2.2).  
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Figure 2.2 Digital fluorescence microscope images and fluorescence spectra (λex = 400 nm) of 
mesoporous silica beads embedded with QDs (a) 480 nm, (b) 560 nm, (c) 620 nm SiQDs. 
 
 Multiple QDs of different sizes and emission wavelengths can be incorporated into single 
mesoporous silica beads. Microscopically, the SiQDs will appear as one color, a blend of the 
different color QDs in the individual bead, but spectrally, multiple emission peaks will be present 
for each color QD. A multitude of unique spectral codes can be produced when using multiple 
QDs in single mesoporous silica beads. The ratio of QDs is precisely controlled by using a 
premixed solution of QDs during preparation which limits the competition between the different 
size QDs into the silica pores. There is a homogenous distribution of color between the particles, 
and SiQDs with high amounts of green QDs appear greener and those with larger amounts of red 
QDs appear redder in color (Figure 2.3). The SiQDs appear yellow for samples with a 1:1 ratio 
of green to red QDs due to the combination of even loading distribution of green and red QDs. 
The 1:2 ratio of green to red QDs appear orange because there is twice the amount of red to 
green QDs. Samples with a 1:4 and 4:1 green to red combination appear almost entirely red or 
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green, respectively because of the minimal amount of green or red in each SiQD. The 
corresponding spectrum of each SiQD solution confirms that the beads do contain both red and 
green QDs. The ability to control these ratios allows for great expansion of possible biolabeling 
tools for bioanalytical applications.  
 
 
 
Figure 2.3 Digital fluorescence microscope images and fluorescence spectra (λex = 400 nm) of 
mesoporous silica beads embedded with green (565 nm) and red (620 nm) QDs at different 
ratios: (a) 1:1, (b) 1:2, (c) 3:1, (d) 1:4, (e) 4:1. 
 
2.4.3 Spectral Analysis of Individual Fluorescent Mesoporous Silica Beads 
 The fluorescence emission spectrum was taken for twenty different beads randomly 
selected from each sample. Their emission peak ratios were averaged and standard deviation for 
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each was calculated. Four beads selected from a sample of 1:4 green to red SiQDs are shown 
with their corresponding spectra (Figure 2.4). The spectrograph allows a single bead to be 
analyzed by collecting data from only a selected group of pixels.  
 
 
Figure 2.4 Fluorescence emission spectra of individual beads from a 1:4 green to red SiQD 
sample. 
 
The average spectrum of twenty randomly selected beads for all green to red fluorescent 
mesoporous silica beads is shown (Figure 2.5) and the average ratios and standard deviation are 
depicted (Table 2.1). 
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Figure 2.5 Average fluorescence emission spectra of 20 individual green to red SiQDs: (a) 1:1, 
(b) 1:2, (c) 3:1, (d) 1:4, (e) 4:1. 
 
Table 2.1 Average ratios, standard deviation, and %RSD of SiQDs. 
Ratio Mean Ratio  % RSD 
1:1 1.12611 0.31837 28% 
1:2 1.99927 0.50158 25% 
3:1 2.75091 0.39365 14% 
1:4 3.85085 0.46017 11% 
4:1 3.72310 0.46361 12% 
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2.4.4 TEOS-coated SiQDs 
 Although QDs are stable inside of the mesoporous silica beads, they should still be 
protected further to ensure minimal leakage of the QDs from the pores. The SiQDs must also be 
functionalized for bioconjugation. One approach is to coat the SiQDs with tetraethyl orthosilicate 
(TEOS). TEOS coats SiQDs through a sol-gel process. The SiQDs are dispersed in ethanol and 
various amounts of TEOS are added with water. TEOS hydrolyzes in the presence of water and 
condenses on the SiO2 hydroxyl groups.
40
 A Si-O-Si siloxane bond is formed between the 
mesoporous silica surface and the TEOS. The concentration of TEOS determines the thickness of 
this silica layer. Coating with TEOS further increases stability of the particles, increases 
functionalization strategies, and enables solubility in aqueous solutions. Fluorescence 
microscopy and emission spectra reveal that increasing the amount of TEOS on the SiQD surface 
causes a blue shift of the emission wavelength. This is advantageous for barcoding because more 
spectral codes can be produced without the need for multiple quantum dots of different sizes.  
   
  
Figure 2.6 SiQD with (a) no TEOS, (b) 25 µL TEOS, (c) 50 µL TEOS, (d) 100 µL TEOS, (e) 
200 µL TEOS. 
a) b) c) 
d) e) 
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Figure 2.7 Fluorescence emission spectra of SiQD composite particles coated with TEOS. 
 
2.4.5 Fluorescence Emission and DLS Measurements of Water-Soluble Thiol and Amine-
Modified SiQD Composite Particles 
 Mesoporous silica quantum dot composite particles were further functionalized with thiol 
(-SH) and amine (-NH2) groups by the addition of 3-mercaptopropyltrimethoxysilane (MPTMS) 
and (3-aminopropyl)triethoxysilane (APTES), respectively. Primary amine groups are 
hydrophilic and positively charged at neutral pH. The presence of primary amines on the SiQDs 
surface will enhance water solubility and initialize them for bioconjugation to antibodies or other 
biological protein molecules. Thiol groups are well known for their coupling strategies to 
biological molecules, typically by binding to maleimide. To promote water solubility, N-
(trimethoxysilylpropyl)ethylenediaminetriacteate trisodium salt was added in addition to 
MPTPS. It is a water soluble silane triol that drives SiQD-SH composites to stability in water.
136
 
Fluorescence images and emission spectra were acquired (Figure 2.8). The SiQDs are well 
dispersed in water and the images portray little to no aggregation of the composite particles 
(Figure 2.9). 
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Figure 2.8 Fluorescence Imaging and Emission Spectra of SiQD-NH2 in H2O. 
   
Figure 2.9 Fluorescence Imaging and Emission Spectra of SiQD-SH in H2O. 
 
Dynamic light scattering (DLS) measurements were obtained for comparison of the SiQD 
composites. Each of the samples is relatively stable in solution based on the zeta potential. 
Typically, the larger the zeta potential the more stable the solution. Based on the polydispersity 
index, however, the samples are not considered very monodisperse; a PDI above 0.1 is 
considered to be moderately dispersed. Nonetheless, the final SiQD composites are soluble in 
water, easily functionalized, and have the potential to be a fluorescent biosensor in immunossays. 
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Table 2.2 Dynamic Light Scattering (DLS) data of SiQD composites. 
Sample Diameter (µm) Polydispersity Index Zeta Potential (mV) 
SiQD 4.503 0.18 -24.32 
SiQD-TEOS 4.512 0.19 -28.84 
SiQD-NH2 4.679 0.15 27.12 
SiQD-SH 4.391 0.11 -25.96 
 
2.5 Conclusions  
 
 The goal of this project was to prepare biocompatible mesoporous silica quantum dot 
composites to be used as detection probes for immunoassay development. Quantum dots are 
highly photostable nanocrystals with exceptional brightness, and they have the extraordinary 
ability to multiplex. Only one excitation source is needed to excite quantum dots of different 
sizes and emission wavelengths. Detection probes used for immunoassays should be soluble in 
water and assay buffers. Water solubility is usually promoted through a surface ligand exchange, 
however, this can decrease brightness and reduce quantum yield. Encapsulation is a more 
reliable route that retains quantum yield and does not diminish the inherent properties of the 
quantum dots.  
 Quantum dots of different emission wavelengths were successfully incorporated into 
mesoporous silica producing a set of spectral codes for use in a multiplex immunoassay. The 
quantum dots are stable inside of the silica due to strong hydrophobic interactions between the 
hydrocarbon chain and TOPO capping ligand. Multiple quantum dots of different sizes and 
different emission wavelengths can be incorporated into one silica composite particle and exhibit 
dual fluorescence emission. This greatly extends the amount of spectral coding available, which 
allows for several analytes to be detected simultaneously. In addition to dual emission silica 
quantum dot composites, adding tetraethyl orthosilicate to the composites causes a blue shift in 
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fluorescence emission. Silica quantum dot composites of different emission wavelengths can be 
prepared without the need for a multitude of quantum dots varying in size. Functionalization of 
the silica composites with thiol or amine groups enables them for bioconjugation with antibodies 
for use in an immunoassay. The functionalized quantum dot silica particles were soluble in water 
without the need for a ligand exchange of the quantum dots. These functionalized silica 
composite particles are the ideal candidate to replace fluorescent organic dyes as biosensing 
detection probes.  
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Chapter 3 
 
Multiplex Detection of Atherosclerosis Biomarkers Using a Mesoporous Silica 
Quantum Dot Based Immunoassay 
 
3.1 Abstract 
 
 Cardiovascular disease (CVD) is the leading cause of death in the U.S. for both men and 
women. CVD is mainly caused by hypertension and atherosclerosis. Atherosclerosis is the 
hardening and narrowing of arteries due to plaque buildup from fat and cholesterol accumulation. 
Plaque rupture can result in heart attack or stroke. Imaging techniques such as X-ray contrast 
angiography, magnetic resonance imaging (MRI), computed tomography (CT), and positron 
emission tomography (PET) have all been used for visualizing plaques, but they do not give 
information about inflammation suggestive of vulnerable plaques. Research has shown the 
presence of biomarkers at different stages of atherosclerosis. Specifically, monocyte 
chemoattractant protein-1 (MCP-1) and interleukin 15 (IL-15) have been identified as early 
markers indicative of atherosclerotic susceptibility. Detection of these biomarkers can provide 
early diagnosis and information for future incidence of the disease. 
 MCP-1 and IL-15 biomarkers were detected utilizing a quantum dot based fluorescence 
immunoassay. Quantum dot mesoporous silica bioconjugates were prepared by encapsulating 
CdSe/ZnS QDs into mesoporous silica and labeling them with antibodies. The fluorescence 
immunoassay was developed to detect both MCP-1 and IL-15 simultaneously. Simultaneous 
detection of biomarkers allows for more rapid diagnoses and can improve disease prognosis. 
50 
 
Antibodies were immobilized to a well plate to capture the specific biomarkers. Quantum dot-
antibody labeled silica bioconjugates were bound to specific biomarkers and the fluorescence 
emission was measured. Multiplex immunoassays have great promise as a diagnostic tool for 
atherosclerosis.  
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3.2 Introduction 
 
 Cardiovascular disease (CVD) is the leading cause of death for men and women in the 
United States accounting for about 1 of every 3 deaths.
1-4
 Over 92 million Americans are living 
with some form of CVD, and related costs are estimated to be more than $316 billion for 2017.
2
 
Plaque builds up in the arteries that supply oxygen-rich blood to the heart; the hardening of the 
plaque and narrowing of the arteries is known as atherosclerosis.
5-6
 Atherosclerosis can lead to 
heart attack or stroke.
1, 6
 Plaque is composed of fat, cholesterol, calcium, and other substances in 
the blood. The hardening and narrowing of the arteries limits blood flow to the heart causing 
angina. Plaque rupture can form acute blood clots, which block blood flow through an artery 
leading to heart attack or stroke.
1
 Atherosclerotic plaques are either stable or susceptible, and 
susceptible plaques are prone to rupture.
1
 Susceptible plaques have a large lipid-rich core, a thin 
fibrous cap, and increased plaque inflammation.
7
 Hardened and narrowed arteries lead to heart 
attack, but researchers are realizing that vulnerable plaques are not always present on the artery 
wall causing blockage.
1, 4
 Many heart attacks occur due to vulnerable atherosclerotic plaques 
inside the artery wall because of large degrees of inflammation.
1, 6
 Fatty low density lipoprotein 
(LDL) particles are taken into the arterial cells, which release cytokines that lead to 
inflammation.
4, 6-7
 The cytokines affect the surface of the artery wall which attracts monocytes 
that turn into macrophages. Macrophages engulf oxidized LDL particles, leading to fatty 
deposits.
6, 8
 Over time, these deposits eventually form plaque within the artery walls.
1
 Bodily 
stresses can cause the thin covering to open and release the contents of the plaque into the 
bloodstream, and the cytokines capture platelets, rapidly forming a blood clot. Such clots can 
substantially or completely block blood flow, causing the surrounding tissue to become oxygen 
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starved. Heart muscle without sufficient oxygen supply cannot contract, resulting in a heart 
attack. Blockage in a brain artery can lead to death of brain cells (stroke). 
 Current atherosclerosis diagnostic methods include blood tests for abnormal levels of 
fats, cholesterol, sugars, and proteins in the blood.
2, 8
 Electrocardiograms (EKG) are also 
commonly used to monitor the heart’s electrical activity; however, an EKG typically shows signs 
of heart damage rather than providing information for future incidence of CVD. Chest x-rays, 
echocardiograms, computed tomography (CT) scans, angiographies, and stress tests are also used 
for diagnosis, but none of these methods provides early detection.
2
 These methods are used to 
confirm that atherosclerotic plaques are already present in the coronary arteries. Magnetic 
resonance imaging (MRI) and positron emission tomography (PET) are being explored to give 
more detailed information about the nature of the plaque buildup. 
 Early diagnosis of atherosclerotic plaque formation could lead to early treatment and 
improved prognosis for CVD. Several biomarkers have recently been identified as indicative of 
atherosclerotic plaques at various stages of plaque development.
8-9
 The biomarkers are present 
from development of precursor legions or fatty streaks to complete lipid-rich plaques.
6, 8, 10
 
Cytokine interleukin 15 (IL-15) and chemokine monocyte chemoattractant protein-1 (MCP-1) 
have been recognized as two fundamental atherosclerotic biomarkers.
9-12
 IL-15 is a 
proinflammatory cytokine expressed in immune cells and atherosclerotic lesions and has shown 
involvement in the increase of macrophage content of plaques.
3, 10, 13
 MCP-1 is a chemokine that 
rises in macrophage-rich regions of atherosclerotic regions.
9, 12, 14
 Chemokines are released in 
response to signals from proinflammatory cytokines such as IL-15.
11
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A quantum dot based fluorescence immunoassay was developed for detection of IL-15 
and MCP-1 atherosclerosis biomarkers. Immunoassays are commonly used to measure and 
quantify the amount or presence of a given molecule primarily through antibody-antigen 
binding.
15-17
 Developing quantum dots in an immunoassay allow for simultaneous detection or 
multiplexing of multiple species.
17-20
 Detection antibodies labeled with quantum dots will exhibit 
fluorescence when the corresponding antigen or protein is present in the sample.
21-22
 Biomarkers 
can easily be identified through this immunoassay, and this capability could lead to earlier 
treatment options for those at risk for atherosclerosis development.  
Previously, a quantum dot based immunoassay was proposed for detection of 
atherosclerosis biomarkers by directly conjugating quantum dots to the atherosclerosis 
antibodies. A ligand exchange was performed to replace the TOPO capping ligand of CdSe/ZnS 
quantum dots with 16-mercaptohexadecanoic acid (MHDA). This exchange permitted water 
solubility, and the quantum dots were covalently linked to the antibodies through EDC coupling. 
The immunoassay successfully detected two biomarkers, but it did not improve on current 
detection limits. Encapsulating quantum dots into mesoporous silica and modifications to the 
immunoassay show potential to improve sensitivity.  
3.3 Experimental Methods 
 
3.3.1 Materials and Reagents. 
All chemicals were used without modification unless otherwise noted. Cadmium oxide (99.99%), 
lauric acid (98%), technical grade (90%) trioctylphosphine oxide (TOPO), technical grade (90%) 
hexadecylamine (HDA), technical grade (90%) trioctylphosphine (TOP), selenium powder 
(99.5%), diethyl zinc solution 1.0 M in heptane, hexamethyldisilathiane, anhydrous methanol 
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(99.8%), chloroform (99.5%), tetraethyl orthosilicate (TEOS), (3-aminopropyl)triethoxysilane 
(APTES), and anhydrous dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. 
Louis, MO). Mesoporous silica particles (5 µm in diameter) with 32 nm C18-modified pores were 
obtained from Phenomenex (Torrance, CA). Ethanol, 200-proof, ACS/USP grade was purchased 
from Pharmco-AAPER (Brookfield, CT). Ethylene glycolbis(succinidmylsuccinate) (EGS, 
99±%) was purchased from ProteoChem (Loves Park, IL). Phosphate buffered saline (PBS) was 
obtained from Calbiochem (Billerica, MA). Mouse monoclonal IL-15 antibody, rabbit polyclonal 
IL-15 antibody, IL-15 protein, mouse monoclonal MCP-1 antibody, rabbit polyclonal MCP-1 
antibody, and MCP-1 protein were purchased from Abcam (Cambridge, MA). Amine reactive 
maleic anhydride activated 96 well plates, sulfosuccinimidyl 4-[N-
maleimidomethyl]cyclohexane-1-carboxylate (Sulfo-SMCC), and Super Block T20 PBS 
blocking buffer were purchased from ThermoFisher Scientific (Waltham, MA). N-
(trimethoxysilylpropyl)ethylenediaminetriacetate, trisodium salt (35% in water) was purchased 
from Gelest. Nanopure deionized and distilled water (18.2 MΩ) purified with a Barnstead 
Nanopure system was used for all experiments. 
3.3.2 Synthesis of TOPO-coated luminescent quantum dots 
 TOPO coated CdSe/ZnS quantum dots were prepared using a slightly modified version of 
a commonly used method developed by Peng.
23-24
 Briefly, 12-13 mg of cadmium oxide (CdO) 
and 180 mg of lauric acid were mixed in a three-neck flask under a nitrogen atmosphere. The 
mixture was heated to 180-200 °C until the CdO fully dissolved in the lauric acid forming a 
clear, colorless solution. Once fully dissolved, 1.94 g of trioctylphosphine oxide (TOPO) and 
1.94 g of hexadecylamine (HDA) were added to the solution under constant stirring. The 
temperature was then increased to 280 °C for 10 minutes before being cooled slowly. 
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Meanwhile, a solution of 80 mg of selenium powder was dissolved in 2 mL of trioctylphosphine 
(TOP). This solution was rapidly injected into the mixture under vigorous stirring upon reaching 
the desired temperature during the cooling process. Size-tunable luminescent quantum dots are 
directly dependent on temperature. The temperature at which the selenium component is injected 
determines the size of the quantum dots synthesized, corresponding to their emission 
wavelength. Typically, the temperature is slowly decreased from 280 °C to 180 °C. The higher 
the temperature upon injection, the larger the quantum dots will be in size. A precursor solution 
for a ZnS shell was prepared: 2 mL of TOP containing 1 mL of diethyl zinc (Zn(Et2)) and 250 
µL of hexamethyldisilathiane ((TMS)2S). This mixture was added dropwise into the solution 
after injection of the selenium. The resulting reaction mixture was kept at 180 °C for 1 h before 
cooling to room temperature. The resulting CdSe/ZnS quantum dots were washed 3 times with 
methanol by centrifugation at 4000 rpm for 10 minutes and redispersed in chloroform. The 
quantum dots were stored at room temperature in the dark. 
3.3.3 Preparation of Fluorescent Mesoporous Silica Beads 
Briefly, 4 mg of mesoporous silica particles averaging 3, 5, or 10 µm in diameter with 32 
nm C18-modified pores were dispersed in 2 mL of butanol. Two hundred microliters of TOPO-
CdSe/ZnS quantum dots were added to the solution under constant stirring. This mixture was 
incubated for 1 hour and washed 3 times with ethanol by centrifugation at 11,000 rpm for 20 
minutes. The fluorescent silica microbeads were visualized using an Olympus IX-71 inverted 
fluorescence microscope and stored at 4 °C.  
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3.3.4 Preparation of TEOS-capped fluorescent mesoporous silica beads 
Silica coated fluorescent mesoporous silica beads were prepared by dispersing 2 mg of 
mesoporous fluorescent silica particles in 2 mL of ethanol and 500 µL of nanopure water. Upon 
stirring, 50 µL of tetraethyl orthosilicate (TEOS) was added. The mixture was incubated 
overnight, centrifuged for 20 minutes at 11,000 rpm and washed with ethanol. The resulting 
TEOS-capped fluorescent mesoporous silica beads were resdispersed in nanopure water and 
stored at 4 °C. 
3.3.5 Amine-Modified SiQDs 
TEOS capped mesoporous silica beads were further modified by the addition of an amine 
group to the surface of the particles. Briefly, 2 mg of TEOS-capped fluorescent mesoporous 
silica beads were dispersed in 2 mL of ethanol. Under constant stirring, 50 µL of (3-
aminopropyl)triethoxysilane (APTES) was added dropwise to the mixture and incubated 
overnight. The mixture was centrifuged for 20 minutes at 11,000 rpm and washed with ethanol. 
The amine-modified particles were resdispersed in nanopure water via ultrasonication and stored 
at 4 °C until further use. 
3.3.5 Thiol-Modified SiQDs 
Mesoporous silica beads were also modified with a thiol group for bioconjugation. 
Quantum dot loaded mesoporous silica beads were dispersed in 1 mL of propanol and 1 mL of 
water. To this solution 100 µL of 3-mercaptopropyltrimethoxysilane (MPTMS) was added while 
stirring. This mixture was incubated overnight and was then washed 3 times with ethanol for 20 
min at 11,000 rpm. The thiol-capped mesoporous silica beads were resdispersed in 1 mL of 
water and 1 mL of propanol and 50 µL of N-(trimethoxysilylpropyl)ethylenediaminetriacetate 
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was added dropwise. The mixture was stirred overnight and was then washed 3 times with 
nanopure water. The resulting particles were dispersed in nanopure water and used immediately 
for bioconjugation. 
3.3.6 Crosslinking of SiQDs to IL-15 and MCP-1 Antibodies 
 Amine modified fluorescent mesoporous silica composites were conjugated to 
atherosclerosis biomarkers via amine-to-amine crosslinking. The composites were air dried, and 
2 mg were dispersed in 1 mL of nanopure water. A solution of ethylene 
glycolbis(succinimidylsuccinate) (EGS) in anhydrous dimethyl sulfoxide (DMSO) was prepared. 
An aliquot of IL-15 or MCP-1 polyclonal detection antibodies was diluted to 10 µg/mL in 500 
µL of phosphate buffered saline (PBS). To the antibody solutions, 500 µL of SiQD-NH2 
composites was added, and 1 µL of EGS in DMSO was added to the mixture. The mixture was 
incubated at room temperature for 20 minutes and washed with nanopure water. The antibody-
bead bioconjugates were redispersed in PBS buffer pH 7.4 and used immediately for 
fluorescence immunoassay.  
Thiol-modified fluorescent mesoporous silica composites were conjugated to 
atheroscloersis biomarkers via thiol-to-amine crosslinking. SiQD-SH composites were dispersed 
in 1 mL of nanopure water. A solution of sulfosuccinimidyl-4-[N-
maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC) in water was prepared. An aliquot 
of IL-15 or MCP-1 polyclonal detection antibodies was diluted to 10 µg/mL in 500 µL of  PBS. 
The sulfo-SMCC was added to the antibody solutions an incubated for 30 min at room 
temperature. Excess crosslinker was removed using a Zeba spin desalting column. Maleimde-
activated antibodies were combined with SiQD-SH composites, incubated for 30 min at room 
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temperature, and washed with nanopure water. Resulting antibody labeled composites were 
redispersed in PBS pH 7.4 and used immediately for fluorescence immunoassays.  
3.3.7 Individual IL-15 and MCP-1 Fluorescent Immunoassays 
 Amine-binding, clear microtiter well plates were washed three times with 200 µL of 
wash buffer (PBS pH 8.0 buffer containing 0.05% Tween 20). After removing the wash buffer, 
100 µL of 25 µg/mL of IL-15 or MCP-1 monoclonal antibodies were added to the wells and 
incubated overnight at room temperature. The excess capture antibodies were removed from the 
wells and 200 µL of SuperBlock blocking buffer was added. The blocking buffer quenches the 
remaining active sites on the well surface. After 1 hour the blocking buffer was removed and the 
wells were washed three times with wash buffer. Varying concentrations of MCP-1 or IL-15 
antigens were added to the wells to bind to the capture antibodies. The well plate was incubated 
at room temperature for 1 hour and washed three times with wash buffer. The detection 
antibody-fluorescent bead conjugates were added to the wells, and the plate was incubated at 
room temperature for 1 hour. Finally, the detection antibody-bead solutions were removed and 
the plate wells were washed with wash buffer three times (Scheme 3.1). 
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Scheme 3.1 Schematic representation of quantum dot fluorescence immunoassays. 
 
3.3.8 Multiplex Fluorescence Immunoassays of IL-15 and MCP-1 
 Fluorescent immunoassays simultaneously detecting IL-15 and MCP-1 were performed 
similarly to individual immunoassays. Amine-binding clear microtiter well plates were washed 
three times with 200 µL of wash buffer. Upon removing the wash buffer, 50 µL of IL-15 
antibodies and 50 µL MCP-1 antibodies at 25 µg/mL in PBS buffer pH 7.4 were added to the 
well plate and incubated overnight at room temperature. The capture antibody solutions were 
removed and the wells were blocked by adding 200 µL of SuperBlock blocking buffer. The plate 
was incubated with blocking buffer for 1 hour at room temperature. The blocking buffer was 
removed and varying concentrations of IL-15 and MCP-1 antigens were added to the well plate 
and incubated for 1 hour at room temperature. The plate was washed 3 times with wash buffer, 
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and 50 µL of IL-15 antibody-bead bioconjugates as well as 50 µL of MCP-1 antibody-bead 
bioconjugates were added to the wells. The antibody-bead bioconjugates were labeled with 
mesoporous silica beads containing quantum dots of different sizes, thereby each having a 
different fluorescence emission maximum. The well plate was incubated for 1 hour at room 
temperature and washed three times with wash buffer. 
3.3.9 Fluorescence Spectroscopy Measurements 
Fluorescence emission spectra were obtained using a SpectraMax M2 spectrofluorometer 
microplate reader (Molecular Devices, Inc.) equipped with a 75 W continuous Xenon flash arc 
lamp as a light source and a photomultiplier (R-3896) detector. The excitation wavelength for all 
samples was 400 nm. Fluorescence emission was measured from 500-750 nm. 
3.3.10 Digital Fluorescence Imaging Microscopy  
 Fluorescence images were taken using a digital fluorescence imaging microscopy 
systems containing an Olympus IX-71 inverted fluorescence microscope equipped with a 100 W 
mercury lamp as a light source and a high performance color charge coupled device (CCD) 
camera (Olympus DP 70). Images were obtained through 10x, 20x, and 40x microscope 
objectives with numerical aperture = 0.5. A filter cube with a 425 ± 20 nm band-pass excitation 
filter, a 465 nm dichroic mirror, and a 475 nm long pass emission filter was used for spectral 
imaging. Image analysis was done using DP Controller software. An exposure time of 10 ms was 
typically used for image acquisition. 
 
 
3.4 Results and Discussion 
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3.4.1 Direct Detection Assay of IL-15 and MCP-1 Biomarkers 
 IL-15 and MCP-1 atherosclerosis biomarkers were identified through a quantum dot 
bioconjugate based fluorescence immunoassay. The reported immunoassay detection limits for 
IL-15 and MCP-1 are 250 pg/mL and 0.2 ng/mL, respectively. The detection of the biomarkers 
was first measured through comparison of a direct detection assay and a sandwich detection 
assay. Direct detection assays do not use capture antibodies, the antigen is non-specifically 
bound directly to the surface of a 96-well plate, and detection antibodies labeled with quantum 
dots are added to bind to the antigens. Sandwich detection assays first bind a capture antibody to 
the surface of the well plate in order to capture more of the antigen protein and increase assay 
sensitivity (Scheme 3.1). Detection of 5 ng/mL IL-15 (Figure 3.1) and 50 ng/mL MCP-1 (Figure 
3.2) were compared using a direct detection and sandwich detection immunoassay. For the 
sandwich immunoassays, a 100 µL solution of 25 µg/mL of monoclonal antibodies IL-15 and 
MCP-1 was used as capture antibodies. The fluorescence emission intensity of the sandwich 
detection assay is 4 times higher for each biomarker indicating that it is more sensitive than the 
direct detection assay. The direct assay was unable to detect biomarker concentrations at the 
current detection limits (data not shown). The biomarkers were nonspecifically adsorbed to the 
well plate surface in the direct assay. Utilization of a sandwich immunoassay provides a more 
sensitive means for detection of IL-15 and MCP-1 biomarkers.  
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Figure 3.1 Fluorescence microscopy imaging of 5 ng/mL of IL-15 from a (a) direct detection 
assay and (b) sandwich detection assay. The individual spots are the QD-antibody bioconjugates 
bound to the antigen present in the well. 
 
 
Figure 3.2 Fluorescence emission of 5 ng/mL IL-15 protein using a direct detection and 
sandwich detection immunoassay. 
a) b) 
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Figure 3.3 Fluorescence microscopy imaging of MCP-1 using a (a) direct detection assay and 
(b) sandwich detection assay. The individual spots are the QD-antibody bioconjugates bound to 
the antigen present in the well. 
 
 
Figure 3.4 Fluorescence emission of 50 ng/mL MCP-1 protein using a direct detection and 
sandwich detection fluorescence immunoassay. 
 
3.4.2 Optimization of Capture Antibody Concentration 
Capture antibody concentration is one of the most important parameters for immunoassay 
development because it determines the amount of antibody that adsorbs onto the well plate 
a) b) 
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surface. Typically, monoclonal antibodies are used as the capture antibody in a sandwich assay 
complex to ensure specificity during the binding of the analyte. Monoclonal antibodies have an 
inherent monovalent affinity toward a single epitope that allows quantification of small 
differences in an antigen. Detection antibodies are usually polyclonal and bind multiple epitopes 
of a target antigen. This forms the “sandwich” with the antigen between two antibodies.  
Capture antibody concentrations for each biomarker were tested between 0 and 50 
µg/mL. The same amount of antigen was used for each assay to test the efficiency of the capture 
antibody immobilization, 5 ng/mL IL-15 and 50 ng/mL MCP-1 were used for investigation. The 
fluorescence intensity increased for both biomarkers from 0 to 25 µg/mL capture antibody 
concentration. Increasing to 50 µg/mL displayed no increase in fluorescence intensity indicating 
maximum loading efficiency at 25 µg/mL.  
 
Figure 3.5 Optimization of capture antibodies at 5 ng/mL of IL-15 (orange) and MCP-1 (green) 
proteins. λex = 400 nm.  
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3.4.3 Individual Fluorescence Immunoassays of IL-15 
 Antibody-labeled-bioconjugates are key components to assay optimization. Mesoporous 
silica quantum dot composites were functionalized with thiols (-SH) and amines (-NH2) to 
explore which crosslinking technique would be most suitable for quantum dot fluorescence 
immunoassays. Thiol groups were introduced to the SiQDs by the addition of (3-
mercaptopropyl)trimethoxysilane (MPTMS) and the resulting SiQD-SH composites were labeled 
with detection antibodies via a sulfosuccinimidyl 4-[N-maleimidomethyl]cylcohexane-1-
carboxylate (sulfo-SMCC) crosslinker (Scheme 3.2). Sulfo-SMCC is a heterobifunctional 
crosslinker containing a maleimide group and an N-hydroxysuccinimide (NHS) ester group that 
promotes covalent coupling of molecules containing amines and sulfhydryls. The maleimide 
group reacts with the thiol groups on the SiQD-SH surface forming stable thioether bonds, and 
the NHS ester on the opposite side of the crosslinker forms an amide bond with the primary 
amines of the antibodies.  
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Scheme 3.2 Reaction scheme for conjugating antibodies with SiQD-SH with Sulfo-SMCC. 
Silica spheres are represented by spheres with green dots (not to scale). 
 
Individual fluorescence immunoassays were done using antibody labeled SiQD-SH 
composites. IL-15 detection antibodies were conjugated to SiQDs containing QDs (λEM = 600 
nm), and MCP-1 detection antibodies were conjugated to SiQDs containing QDs (λEM = 560 
nm). The capture antibodies were immobilized to the well plate and blocked with SuperBlock 
blocking buffer. The blocking buffer quenches any remaining active sites on the well plate 
surface. IL-15 antigens were added followed by the SiQD-antibody bioconjugates. The 
fluorescence intensity increased with increasing concentrations of IL-15 from 1 pg/mL to 5 
ng/mL (Figure 3.4). The individual wells were visualized using a fluorescence microscope, and 
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the images show an increasing number of particles as the concentration of IL-15 increases. There 
were no particles attached to the wells at 0 µg/mL of IL-15. If there is no antigen present to bind 
to the immobilized capture antibodies then the fluorescent detection antibody conjugates will 
have nothing to bind to and should not exhibit any fluorescence. Additionally, MCP-1 antigens 
were added to wells prepared with IL-15 capture antibodies, and there was no fluorescence 
detected. IL-15 detection antibodies are not specific to MCP-1 and will not bind to them.  
 
Figure 3.6 Fluorescence microscopy imaging of IL-15: a) 5 ng/mL IL-15 with MCP-1 labeled 
SiQDs, b) 5 ng/mL MCP-1 antigen, c) 0 µg/mL, d) 1 pg/mL, e) 5 pg/mL, f) 50 pg/mL, g) 0.5 
ng/mL, and h) 5 ng/mL. 
a) b) c) 
d) e) f) 
g) h) 
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Figure 3.7 Fluorescence emission spectra of IL-15. 
 
 A similar assay was performed to quantify MCP-1 antigens using SiQD-SH detection 
antibody bioconjugates. MCP-1 capture antibodies were adsorbed to the well plate and blocked 
with blocking buffer. Different dilutions of MCP-1 antigens were added to the wells to bind to 
the capture antibodies. The detection antibodies bioconjugates were added to the wells and the 
fluorescence intensity was measured. Fluorescence intensity increased from 50 pg/mL to 50 
ng/mL of the MCP-1 antigen (Figure 3.5). Microscopy images confirm the increasing number of 
particles bound to the well plate. Again, no particles were attached to the plate where no antigen 
was present or where IL-15 antigens were added. The IL-15 antigens will not attach to the MCP-
1 capture antibodies nor will MCP-1 detection antibodies bind to any MCP-1 that may have non-
specifically adsorbed to the well plate. Results indicate that the sandwich immunoassay is 
sensitive and specific which is ideal for diagnostic applications. 
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Figure 3.8 Fluorescence microscopy imaging of MCP-1: a) 5 ng/mL MCP-1 with IL-15 labeled 
SiQDs, b) 5 ng/mL IL-15 antigen, c) 0 µg/mL, d) 50 pg/mL, e) 0.5 ng/mL, f) 5 ng/mL, and g) 50 
ng/mL. 
d) 
g) 
e) 
a) b) c) 
f) 
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Figure 3.9 Fluorescence emission spectra of MCP-1. 
 
 The individual immunoassays were also performed using detection antibodies conjugated 
to amine-modified SiQDs. Antibodies were coupled to SiQDs via amine-to-amine crosslinking 
using ethylene glycolbis[succinimidylsuccinate] (EGS). Unlike sulfo-SMCC, EGS is a 
homobifunctional crosslinker containing two NHS ester reactive groups. Each NHS ester will 
bind to an amine group on the antibody as well as to an amine group on the SiQD (Scheme 3.3). 
NHS esters react with ε-amine groups present on lysine residues of antibodies as well as α-amine 
groups forming covalent amide bonds. N-hydroxysuccinimide is released during the reaction 
performed at neutral pH. NHS esters readily hydrolyze especially with increasing pH, so 
antibodies coupled via EGS should be used immediately for affinity immunoassays. IL-15 
detection antibodies were coupled to SiQDs containing 600 nm QDs, and MCP-1 detection 
antibodies were coupled to SiQDs containing 560 nm QDs. The fluorescence intensity of IL-15 
increased from 1 pg/mL to 5 ng/mL (Figure 3.6), and the fluorescence intensity of MCP-1 
increased from 50 pg/mL to 50 ng/mL (Figure 3.7). Results were consistent with individual 
assays performed using antibody labeled SiQDs coupled using sulfo-SMCC.  
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Scheme 3.3 Reaction scheme for conjugating antibodies with SiQD-NH2 composites with EGS. 
Silica spheres are represented by spheres with green dots (not to scale). 
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Figure 3.10 Fluorescence microscopy imaging of IL-15: a) 5 ng/mL IL-15 with MCP-1 labeled 
SiQDs, b) 5 ng/mL MCP-1 antigen, c) 0 µg/mL, d) 1 pg/mL, e) 5 pg/mL, f) 50 pg/mL, g) 0.5 
ng/mL, and h) 5 ng/mL. 
 
Figure 3.11 Fluorescence emission spectra of IL-15. 
a) b) c) 
d) e) f) 
g) f) 
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Figure 3.12 Fluorescence microscopy imaging of MCP-1: a) 5 ng/mL MCP-1 with IL-15 labeled 
SiQDs, b) 5 ng/mL IL-15 antigen, c) 0 µg/mL, d) 50 pg/mL, e) 0.5 ng/mL, f) 5 ng/mL, and g) 50 
ng/mL. 
 
a) b) c) 
d) e) f) 
g) 
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Figure 3.13 Fluorescence emission spectra of MCP-1. 
 
3.4.5 Multiplex Immunoassay of IL-15 and MCP-1 
 IL-15 and MCP-1 biomarkers were detected simultaneously through a multiplex quantum 
dot fluorescence immunoassay. A mixture of IL-15 and MCP-1 capture antibodies at 25 µg/mL 
was added to the surface of the well plate. In this manner, the plate was then activated for capture 
of both antigens. Different combinations of IL-15 and MCP-1 biomarkers were added to bind to 
the capture antibodies. Antibody-labeled silica composite particles were added, and the well 
plate was analyzed. SiQDs labeled with IL-15 detection antibodies contained 600 nm emission 
quantum dots, and SiQDs labeled with MCP-1 detection antibodies contained 560 nm emission 
quantum dots.  Both biomarkers were able detected simultaneously below the current limits of 
detection. Microscopy imaging clearly shows the presence of both biomarkers through the 
different colored particles bound to the well plate surface (Figure 3.14). The fluorescence 
emission spectra clearly show two peaks, one corresponding to each biomarker (Figure 3.15).  
Simultaneous detection of both atherosclerotic biomarkers using a sensitive sandwich 
immunoassay can allow for earlier and more rapid diagnostic and treatment assessments. 
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Figure 3.14 Multiplexing of IL-15 and MCP-1: a) 50 ng/mL MCP-1 and 5 ng/mL IL-15, b) 50 
ng/mL MCP-1 and 5 ng/mL IL-15, c) 5 ng/mL MCP-1 and 5 ng/mL IL-15.  
 
 
Figure 3.15 Multiplex Immunoassay of IL-15 and MCP-1. 
3.5 Conclusions 
 
 The goal of this study was to develop a quantum dot based fluorescence immunoassay 
using mesoporous silica quantum dot composite particles as the detection antibody label in order 
to detect atherosclerosis biomarkers IL-15 and MCP-1. Two different conjugation methods for 
coupling the detection antibodies to the SiQDs were explored. SiQDs were functionalized with 
a) b) c) 
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thiol and amine groups to enable them for bioconjugation to the antibodies. Coupling of the 
SiQD composites was achieved through crosslinking agents, sulfo-SMCC and EGS for the thiol 
and amine groups, respectively. Both conjugation methods yielded similar detection of the 
biomarkers. A direct detection assay was initially performed for comparison with a sandwich 
immunoassay. The direct assays for IL-15 and MCP-1 were unable to improve detection of the 
biomarkers. Direct detection assays nonspecifically adsorb the antigen directly to the surface of 
the well plate, and by adding a capture antibody, more of the antigen is bound, thereby 
improving assay sensitivity. Individual fluorescence sandwich immunoassays were performed, 
and detection limits of 1 pg/mL of IL-15 and 50 pg/mL of MCP-1 were achieved. These are an 
improvement from currently reported detection of IL-15 and MCP-1 biomarkers. Multiplex 
detection of the biomarkers was also attempted. Initial results show that both IL-15 and MCP-1 
can be detected simultaneously using the quantum dot based fluorescence immunoassay, 
however, more optimization needs to be explored in order to reproducibly quantify the biomarker 
concentrations. 
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Chapter 4 
 
Synthesis of Quantum Dot Encapsulated Human Serum Albumin 
Nanocomposites 
 
4.1 Abstract 
 Human serum albumin nanoparticles (HSAPs) have been utilized for encapsulation of a 
variety of materials due to the versatile and unique ligand binding properties of HSA. A wide 
array of compounds can functionalize HSAPs for multimodal use. Drugs are commonly loaded 
into HSAPs for targeted drug delivery treatments. Organic fluorophores have also been used in 
HSAPs for imaging and tracking purposes. Quantum dots (QDs) exhibit many advantages over 
organic fluorophores and may be better tools for diagnostic imaging. QDs were loaded into 
HSAPs for exploration of immunoassay development. CdSe/ZnS QDs were added to a stock 
solution of HSA followed by ethanolic desolvation. Crosslinking of the nanoparticles was 
initiated by glutaraldehyde. The resulting QD-loaded human serum albumin nanoparticles (HSA-
QDs) were employed in a fluorescence immunoassay to detect atherosclerosis biomarkers IL-15 
and MCP-1.  
 HSA-QDs were conjugated to IL-15 and MCP-1 antibodies through EDC/NHS coupling 
which forms amide bonds between carboxylic acids and primary amine groups. The 
atherosclerosis biomarkers were detected individually, however, the detection limits did not 
improve based on previous immunoassays.  
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4.2 Introduction 
 
 Human serum albumin (HSA) is the most abundant protein in blood plasma and has 
unique ligand binding capabilities making it ideal for many bioapplications.
1
  HSA is 
biocompatible, biodegradable, and can conjugate drugs or other substances through attachment 
to functional groups.
2-3
 Formation of human serum albumin nanoparticles (HSAPs) through 
desolvation and crosslinking creates functional nanocarriers for encapsulating a multitude of 
molecules.
4-7
  Encapsulation of drug molecules into HSAPs has been shown to significantly 
improve drug delivery in vivo. Chemotherapeutic drug agents are often highly toxic, water 
insoluble, and unable to penetrate the blood brain barrier.
8
 Loading these drugs into HSAPs 
enables efficient transport directed to tumor sites because of how readily HSAPs are tolerated by 
the human body.
4, 9-10
 HSAPs also offer precise control over release of chemotherapeutic agents 
making them ideal nanocarriers for disease treatment assessments and in clinical settings.
8, 11-12
  
 Fluorescent organic dyes have been employed as trackers in HSAPs to image cellular 
labeling and to mimic drug release for targeted delivery studies.
13
 Encapsulation of organic and 
inorganic materials into HSAPs through covalent bonding has shown to be robust and stable. 
Loading quantum dots into HSAPs could further enhance their utility range by extending their 
reach to applications where fluorescent dyes are limited.
14-15
 Fluorescent organic molecules are 
susceptible to photobleaching and have a short fluorescence lifetime.
16-18
 Incorporating quantum 
dots (QDs) into HSAPs may enhance their brightness and enable them as useful fluorescent 
probes. QDs are stable, have a long fluorescence lifetime, and resistant to photobleaching 
relative to organic dyes.
18-20
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Immunoassay performance is measured by specificity, sensitivity, and reproducibility. 
Development of reliable immunoassays requires optimization of the influential factors that affect 
performance and consistency. The detection probes used to quantify analytes in immunoassays 
are crucial to improving sensitivity and detection limits.
17, 21-22
 HSAPs are highly biocompatible 
and easily functionalized due to the numerous charged amino acids on the protein surface.
1, 8, 23
 
Their high specificity could enable them to be new and efficient tools for quantitative analysis. 
Early biomarker detection is critical for diagnostic assessment to improve disease prognosis.  
Encapsulating QDs into HSAPs will permit multiplexing which allows for simultaneous 
detection of antigens and can improve diagnostic capabilities.   
4.3 Experimental Methods 
 
4.3.1 Materials and Reagents 
 All chemicals were used as received without modification unless otherwise noted. 
Cadmium oxide (99.99%), lauric acid (98%), technical grade (90%) trioctylphosphine oxide 
(TOPO), technical grade (90%) hexadecylamine (HDA), technical grade (90%) 
trioctylphosphine (TOP), selenium powder (99.5%), diethyl zinc solution 1.0 M in heptane, 
hexamethyldisilathiane, anhydrous methanol (99.8%), chloroform (99.5%), human serum 
albumin, lyophilized powder ( 97%), aqueous glutaraldehyde (8%), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC), and sulfo-N-
hydroxysulfosuccunimide (sulfo-NHS) were purchased from Sigma-Aldrich (St. Louis, MO). 
Ethanol, 200-proof, ACS/USP grade was purchased from Pharmco-AAPER (Brookfield, CT). 
Phosphate buffered saline (PBS) was obtained from Calbiochem (Billerica, MA). Mouse 
monoclonal IL-15 antibody, rabbit polyclonal IL-15 antibody, IL-15 protein, mouse monoclonal 
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MCP-1 antibody, rabbit polyclonal MCP-1 antibody, and MCP-1 protein were purchased from 
Abcam (Cambridge, MA). Amine reactive maleic anhydride activated 96 well plates and Super 
Block T20 PBS blocking buffer were purchased from ThermoFisher Scientific (Waltham, MA). 
Nanopure deionized and distilled water (18.2 M) purified with a Barnstead Nanopure system 
was used for all experiments.   
4.3.2 Synthesis of TOPO-capped CdSe/ZnS Quantum Dots 
 TOPO coated CdSe/ZnS quantum dots were prepared using a slightly modified version of 
a commonly used method developed by Peng et al.
24-25
 Briefly, 12-13 mg of cadmium oxide 
(CdO) and 180 mg of lauric acid were mixed in a three-neck flask under a nitrogen atmosphere. 
The mixture was heated to 180-200 °C until the CdO fully dissolved in the lauric acid forming a 
clear, colorless solution. Once fully dissolved, 1.94 g of trioctylphosphine oxide (TOPO) and 
1.94 g of hexadecylamine (HDA) were added to the solution under constant stirring. The 
temperature was then increased to 280 °C for 10 minutes before being cooled slowly. 
Meanwhile, a solution of 80 mg of selenium powder was dissolved in 2 mL of trioctylphosphine 
(TOP). This solution was rapidly injected into the mixture under vigorous stirring upon reaching 
the desired temperature during the cooling process. Size-tunable luminescent quantum dots are 
directly dependent on temperature. The temperature at which the selenium component is injected 
determines the size of the quantum dots synthesized, corresponding to their emission 
wavelength. Typically, the temperature is slowly decreased from 280 °C to 180 °C. The higher 
the temperature upon injection, the larger the quantum dots will be in size. A ZnS shell was 
prepared: 2 mL of TOP containing 1 mL of diethyl zinc (Zn(Et2)) and 250 µL of 
hexamethyldisilathiane ((TMS)2S). The shell was added dropwise into the solution after injection 
of the selenium. The resulting reaction mixture was kept at 180 °C for 1 hour before cooling to 
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room temperature. The resulting CdSe/ZnS quantum dots were washed 3 times with methanol by 
centrifugation at 4000 rpm for 10 minutes and redispersed in chloroforms. The quantum dots 
were stored at room temperature in the dark. 
4.3.3 Synthesis of Quantum Dot Loaded Human Serum Albumin Nanoparticles 
Human serum albumin nanoparticles (HSAPs) were synthesized using a commonly used 
desolvation method. A stock solution of human serum albumin (HSA) in water was prepared by 
dissolving 100 mg of HSA into 1 mL of nanopure water. The pH of this solution was around 7. 
To a 20 mL scintillation vial, 200 µL of the HSA stock solution was added along with 500 µL of 
CdSe/ZnS quantum dots. The solution was stirred using a micro stir bar, and 3 mL of 100% 
ethanol was added using a peristaltic pump at a rate of 1 mL/min. To begin the crosslinking of 
the HSA, 4.7 µL of glutaraldehyde was added to the HSAP solution. After stirring for 24 hours, 
the particles were centrifuged for 25 minutes at 13,000 rpm and washed twice with a 1:3 water-
to-ethanol mixture. The resulting quantum dot loaded human serum albumin nanoparticles 
(HSAP-QDs) were resdispersed in nanopure water via ultrasonication and stored at 4 °C.  
4.3.4 Crosslinking of HSAP-QDs to IL-15 or MCP-1 antibodies 
Human serum albumin nanoparticles loaded with quantum dots (HSAP-QDs) were 
crosslinked to atherosclerosis biomarkers for fluorescence assay detection using classic EDC 
coupling methods. Carboxylic acid groups (-COOH) on the surface of the HSAP-QD particles 
are coupled with the amine groups (-NH2) on the surface of the antibody. Typically, 500 µL of 
HSAP-QDs were mixed with 20 µL of 30 mg/mL EDC and 20 µL of 30 mg/mL sulfo-NHS. The 
mixture was vortexed for 20 minutes at room temperature in order to activate the free carboxylic 
acid groups on the HSAP-QD nanoparticles. Next, 500 µL of IL-15 or MCP-1 antibodies were 
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added and the mixture was gently stirred for 2 hours. The resulting conjugate particles were 
separated by centrifugation at 13,000 rpm for 10 minutes, and they were washed twice with PBS 
buffer at pH 7.4. They were redispersed in PBS buffer at pH 7.4 via ultrasonication and used 
immediately for fluorescence assay detection. 
4.3.5 Individual Fluorescence Immunoassays of IL-15 and MCP-1 
Fluorescent immunoassays of atherosclerosis biomarkers IL-15 and MCP-1 were 
performed similarly to previous methods. Amine-binding, clear microtiter well plates were 
washed three times with 200 µL of wash buffer (PBS pH 8.0 buffer containing 0.05% Tween 
20). After removing the wash buffer, 100 µL of 25 µg/mL concentrations of IL-15 or MCP-1 
capture antibodies were added to the wells and incubated overnight at room temperature. The 
capture antibodies were removed from the wells and 200 µL of Super Block blocking buffer was 
added and incubated at room temperature for 1 hour. The wells were washed three times with 
wash buffer after removing the blocking buffer. Varying concentrations of MCP-1 or IL-15 
antigens were added to the wells for binding to the capture antibodies. The plate was incubated at 
room temperature for 1 hour and then washed three times with wash buffer. The detection 
antibody-fluorescent HSAP-QD conjugates were added to the wells, and the plate was incubated 
at room temperature for 1 hour. Finally, the detection antibody-HSAP-QD solutions were 
removed and the plate wells were washed with wash buffer 3 times. 
4.3.6 Multiplex Fluorescence Immunoassays of IL-15 and MCP-1 
Fluorescent immunoassays simultaneously detecting IL-15 and MCP-1 were performed similarly 
to individual immunoassays with slight modifications. Amine-binding, clear microtiter well 
plates were washed three times with 200 µL of wash buffer (PBS pH 8.0 buffer containing 
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0.05% Tween 20). Upon removing the wash buffer, 50 µL of IL-15 and 50 µL of MCP-1 capture 
antibodies at 25 µg/mL in PBS buffer pH 7.4 were added to the well plate and incubated 
overnight at room temperature. The capture antibody solutions were removed and the wells were 
blocked by adding 200 µL of Super Block blocking buffer. The plate was incubated with 
blocking buffer for 1 hour at room temperature. The blocking buffer was removed and varying 
concentrations of IL-15 and MCP-1 antigens were added to the well plate and incubated for 1 
hour at room temperature. The plate was washed three times with wash buffer, and 50 µL of IL-
15 antibody-HSAP-QD (λEX = 600 nm) composites as well as 50 µL of MCP-1 antibody-HSAP-
QD (λEX = 560 nm) composites were added to the wells. The antibody-HSAP-QD composites 
contained quantum dots of different sizes, thereby each having a different fluorescence emission 
maximum which allows for multiplexing. The well plate was incubated for 1 hour at room 
temperature and washed three times with wash buffer. 
4.3.6 Fluorescence Spectroscopy Measurements 
 Fluorescence emission spectra were obtained using a SpectraMax M2 spectrofluorometer 
microplate reader (Molecular Devices, Inc.) equipped with a 75 W continuous Xenon flash arc 
lamp as a light source and photomultiplier (R-3896) detector. The excitation wavelength for all 
samples was 420 nm. Fluorescence emission was measured from 450-750 nm.  
4.3.7 Digital Fluorescence Imaging Microscopy 
 Fluorescence images were taken using a digital fluorescence imaging microscopy system 
containing an Olympus IX-71 inverted fluorescence microscope equipped with a 100 W mercury 
lamp as a light source and a high performance color charge coupled device camera (CCD) 
(Olympus DP 70). Images were obtained through 10x, 20x, 40x, and 60x microscope objectives 
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with numerical aperture = 0.5. A filter cube with a 425 ± 20 nm band-pass excitation filter, a 465 
nm dichroic mirror, and a 475 nm long pass emission filter was used for spectral imaging. Image 
analysis was done using DP Controller software. An exposure time of 10 ms was typically used 
for image acquisition. 
4.3.8 Dynamic Light Scattering Measurements 
 Average particle size, zeta potential, and mobility of HSAP-QD composites were 
determined through dynamic light scattering. The values were obtained using a Mobius dynamic 
light scattering instrument (Wyatt Technology Corporation, Santa Barbara, CA) at 25 °C. 
Samples were dissolved and diluted in nanopure water prior to analysis. 
4.4 Results and Discussion 
 
4.4.1 Fluorescence Emission of HSA-QDs 
 Human serum albumin nanoparticles (HSAPs) were loaded with CdSe/ZnS QDs through 
ethanolic desolvation. The QDs were mixed with a stock solution of HSA in water. Inorganic 
QDs are water-insoluble, however, upon addition of ethanol, the albumin matrix was denatured 
and aggregates of HSA and QDs were formed. A glutaraldehyde crosslinking agent was added to 
bind amines from lysine and arginine residues on the albumin surface. The QDs were 
encapsulated inside the nanoparticle during formation due to hydrogen bonding with the side 
chains of the hydrophobic amino acids and the TOPO capping ligand on the QD surface.
1, 26-27
 
 Fluorescence emission of HSAP-QDs was measured using a SpectraMax Pro M2 
spectrometer, and fluorescence microscopy images were taken using an inverted fluorescence 
microscopy, Olympus IX71. HSAPs range from 100-200 nm in diameter, which is too small to 
87 
 
be visualized individually via fluorescence microscopy. However, aggregates are visible, and 
overall fluorescence emission can be observed in the digital images. In addition to the QD 
loading, a fluorescent dye, rhodamine 6G chloride, was encapsulated into the HSAPs for 
comparison. Rhodamine 6G chloride is commonly used as a fluorescent tracer, and it exhibits a 
yellow-green fluorescence emission. Empty HSAPs without any dye or QD loaded exhibited no 
fluorescence emission, while HSAPs loaded with rhodamine, QD-600 and QD-560 displayed 
their respective fluorescence emission wavelengths. Human serum albumin has a natural weak 
green fluorescence (Figure 4.1). Loading the HSAPs with QD-560 or rhodamine demonstrated a 
considerable difference through microscopy. After several washings of the encapsulating 
HSAPs, the supernatants of the HSAPs showed no fluorescence. It appears there may be some 
background or free QDs in the solution, but this is actually due to aggregation of the HSAPs. 
Both QD-560 nm and rhodamine 6G chloride appear green when fluorescing, and HSAPs loaded 
with 600 nm QDs should appear orange-reddish in color. However, in samples of HSAP-QD-
600, there are green aggregates dispersed throughout the solution (Figure 4.3). This indicates that 
not all of the HSAPs contain QDs and the loading is not evenly distributed during synthesis. 
Inefficient loading is a major limitation for multiplexing, as aggregates will not be 
distinguishable microscopically. The green aggregates seen throughout are unloaded HSAPs. 
 
Figure 4.1 Digital Fluorescence Microscopy Image and Emission Spectra of empty HSAPs. 
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Figure 4.2 Digital Fluorescence Microscopy Image and Emission Spectra of HSAPs loaded with 
Rhodamine 6G chloride. 
 
 
Figure 4.3 Digital Fluorescence Microscopy Image and Emission Spectra of HSA-QD (600 nm). 
 
 
Figure 4.4 Digital Fluorescence Microscopy Image and Emission Spectra of HSA-QD (560 nm). 
 
Dynamic light scattering (DLS) measurements were taken to observe any changes in the 
sizes of the HSAPs after loading with a fluorophore or with quantum dots (Table 4.1). The 
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expected diameter range of QDs synthesized is 100 – 200 nm. All samples exhibited particle 
diameter within this range, however, only the unloaded HSAPs exhibited true monodispersity. 
QD-loaded and dye-loaded HSAPs were relatively monodisperse, but there is some aggregation 
present within those samples. The zeta potential (mV) for all of the samples indicates that they 
nanoparticle systems are stable. Larger zeta potentials are characteristic of stable colloidal 
systems.
7, 28
 
Table 4.1 Dynamic Light Scattering (DLS) data for HSAPs. 
 HSAP HSA-Rhodamine 
HSA-QD (560 
nm) 
HSA-QD (600 
nm) 
Particle Diameter 
(nm) 
194.73 ± 2 143.10 ± 3 162.79 ± 1 201.19 ± 1 
Polydispersity 
Index (PDI) 
0.0943 0.1261 0.1243 0.1316 
Zeta Potential 
(mV) 
-24 -24 -22 -26 
 
4.4.2 Photostability 
 Conventional organic dyes are known for not being very photostable and having 
susceptibility to photobleaching.
15, 29
 Photobleaching occurs when a fluorophore loses the ability 
to fluoresce due to the cleaving of covalent bonds and interactions with the surrounding 
environment.
16, 30
 When electrons transition from an excited singlet state to an excited triplet 
state, the fluorophore can interact with other molecules and undergo chemical modification.
16
 
Excited electrons remain in the triplet state longer than in the singlet state, thus giving more time 
to interact with the environment. The rate at which a molecule experiences photobleaching is 
dependent on its molecular structure and the surrounding environment, but in many cases for 
organic dyes, the number of excitation and emission cycles is known. Photobleaching is a major 
limitation for fluorescence microscopy, and fluorescent materials that do not lose their ability to 
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fluoresce are ideal for labeling and imaging. A typical organic dye may experience 
photobleaching after absorption of 10
5 
photons while CdSe/ZnS QDs have been reported to 
absorb 10
8
 photons prior to any photobleaching.
15
 QDs are inherently brighter than organic dyes 
with high molar extinction coefficients and comparable quantum yields, yet they have more 
stability, which accounts for the decrease in photobleaching susceptibility.
15, 31
 
 Quantum dot loaded HSAPs were compared with HSAPs loaded with rhodamine 6G 
chloride. The nanoparticle solutions were illuminated for 2 hours using a 100 W mercury lamp. 
Fluorescence emission was measured every 15 minutes, and it is evident that HSAPs loaded with 
QDs have higher photostability than rhodamine 6G chloride (Figure 4.5). The fluorescence 
emission intensity decreased about 10% for HSAP solutions containing 600 nm or 560 nm QDs. 
Particle solutions containing rhodamine 6G chloride decreased 40%. 
 
Figure 4.5 Photostability measurements of HSA-QDs and HSA-Rhodamine dye. 
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4.4.3 HSAP Leakage and Stability 
 Fluorescence intensity of QD-loaded HSAPs and rhodamine loaded HSAPs was 
monitored for 10 days to examine if there was any leakage of QDs or fluorophore from the 
HSAP core (Figure 4.6). HSAPs have shown capabilities of encapsulating inorganic materials, 
but the limited availability of hydrophobic amino acids causes the loading efficiency to be lower 
than hydrophilic materials. Aggregation of QDs inside of the HSAPs may also affect the 
integrity of the albumin matrix that could lead to some leakage. Nanomaterials with significant 
leakage are not suitable for in vivo applications as nanocarriers especially if leakage will release 
toxic materials. Significant leakage from nanoparticle also presents limitations to long-term 
labeling or monitoring in vitro applications. The supernatant of the HSAP solutions was 
measured and any fluorescence emission was recorded. There was relatively little to no leakage 
of dye or QDs from the HSAPs over the first couple of days, but after day 3, the intensity of 
rhodamine in the supernatant started to increase. QD fluorescence was evident by day 5, so even 
though they lasted longer, some leakage still occurred. The fluorescence intensity in the 
supernatants continued to rise steadily through day 10 for all HSAP samples. After HSAP 
preparation, the nanoparticles should be used immediately in order to ensure optimal brightness, 
stability, and minimal leakage of the fluorophore.  
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Figure 4.6 Fluorescence Intensity of Fluorophore Released from HSAPs over 10 Days. 
 
4.4.4 Fluorescence Immunoassays of IL-15 and MCP-1 
 QD-loaded HSAPs were used in fluorescence immunoassays to measure the presence of 
atherosclerosis biomarkers IL-15 and MCP-1. Sandwich immunoassays were utilized in order to 
increase the opportunity for antigen-antibody binding and improve assay sensitivity (Scheme 
4.1). IL-15 or MCP-1 antibodies were immobilized on a well plate surface and incubated at 37 
C for 1 hour. The well plate was blocked with SuperBlock blocking buffer to quench remaining 
active sites on the well plate surface. Different concentrations of each antigen were then added to 
the well plate for binding by the capture antibodies.  
Meanwhile, detection antibodies were conjugated to the HSAP-QDs via EDC coupling of 
carboxylic acids (-COOH) and amines (-NH2) on the HSAP and antibody surfaces. EDC 
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coupling is a classic bioconjugation reaction for biomolecules.
32-33
 EDC reacts with carboxylic 
acids forming an amine-reactive O-acylisourea intermediate.
34-35
 The intermediate is highly 
susceptible to hydrolysis, unstable, and short-lived.
15, 31
 The targeted amine group must quickly 
find the active carboxylate prior to hydrolysis or the coupling reaction will not occur. Adding 
sulfo-NHS overcomes this issue by converting the intermediate to an amine-reactive sulfo-NHS 
ester intermediate and increasing its stability. The sulfo-NHS ester intermediate reacts with the 
amine groups on the detection antibody and forms the HSAP-QD-antibody bioconjugates. The 
resulting bioconjugates are stored in PBS buffer and used immediately for assay detection.  
 
Scheme 4.1 Reaction scheme for conjugating antibodies with HSAP-QD through EDC/NHS 
coupling. 
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HSAP-QDs containing 600 nm emission QDs were coupled with IL-15 detection 
antibodies. The QD-antibody bioconjugates were added to the well plate and allowed to bind to 
the IL-15 antigens for 1 hour before washing. The plate was then visualized through fluorescence 
microscopy, and the emission was measured using the microplate reader. Microscopy images 
show an increasing amount of orange-reddish HSAP-QDs as the concentration of IL-15 is 
increased. The particles in the images are not individual HSAPs; because HSAPs are too small to 
seen individually via fluorescence microscopy, aggregates are displayed in the images. There 
does not appear to be an even distribution of color throughout the images again indicating that 
the QDs are not evenly distributed throughout the HSAP solution. The assay was able to detect 
as low as 50 pg/mL IL-15, but this is not as sensitive as other reported detection methods (Figure 
4.8). The antigen-antibody binding is specific as expected; HSAP-QDs conjugated to MCP-1 
detection antibodies did not show fluorescence emission when added to wells containing IL-15 
antigens (data not shown). 
 
Figure 4.7 Digital Fluorescence Microscopy of IL-15 sandwich assay detection: a) 50 pg/mL, b) 
0.5 ng/mL, and c) 5 ng/mL.  
 
a) b) c) 
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Figure 4.8 Fluorescence emission spectra of IL-15 using HSAP-QD (600 nm). 
 
 HSAP-QDs containing 560 nm emission QDs were coupled to MCP-1 antibodies, and 
results were similar to the IL-15 assays. Microscopy imaging shows an increase in the number of 
HSAP-QD aggregates as the concentration of MCP-1 is increased (Figure 4.9). There is likely 
inefficient loading of QDs in these samples as well, but unloaded HSAPs are not distinguishable 
from 560 nm QD-HSAPs. Fluorescence intensity measurements revealed consistent data with 
imaging, the intensity increased as concentration increased (Figure 4.10). This assay had a limit 
of detection of 0.5 ng/mL MCP-1, which is not an improvement over current detection methods.  
 
Figure 4.9 Digital Fluorescence Microscopy of MCP-1 sandwich assay detection: a) 0.5 pg/mL, 
b) 5 ng/mL, and c) 50 ng/mL. 
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Figure 4.10 Fluorescence emission spectra of MCP-1 using HSAP-QD (560 nm). 
 
 A multiplex immunoassay was performed using HSAP-QDs containing 600 nm and 560 
QDs conjugated to IL-15 and MCP-1 detection antibodies, respectively. Capture antibody 
solutions containing both IL-15 and MCP-1 antibodies were added to the wells for 
immobilization. The well plate was blocked, and both IL-15 and MCP-1 antigen solutions were 
added to the same wells. The QD-antibody bioconjugates were finally added to measure the 
presence of the antigens. Upon washing, the well plate was visualized via fluorescence 
microscopy, and the fluorescence emission was measured (Figure 4.11). The fluorescence 
intensity clearly shows two peaks: one at 560 nm and one at 600 nm indicating that both 
biomarkers were present and detected simultaneously. This shows potential in the use of an HSA 
based immunoassay; however, the different particles are not discernable through fluorescence 
microscopy. If HSAP-QDs with 600 nm QDs are not efficiently loaded and samples contain 
significant empty HSAPs, these particles could not be distinguished from HSAP-QDs containing 
560 nm QDs. In order to utilize QDs in this assay, QD loading would have to be evaluated 
further if there is any potential use for detection of biomarkers.  
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Figure 4.11 Multiplex Detection of IL-15 and MCP-1 using HSAP-QD (600 nm) conjugated to 
IL-15 and HSAP-QD (560 nm) conjugated to MCP-1. 
 
4.5 Conclusions 
 
 In summary, CdSe/ZnS quantum dots were used for encapsulation into human serum 
albumin nanoparticles. HSAPs have tremendous versatility throughout a wide array of biological 
applications. They have extraordinary ligand binding properties that enable them to encapsulate 
different types of nanomaterials including inorganic, water-insoluble materials. This feature 
provides opportunities for QDs and other inorganic materials to be more useful in bioanalytical 
and clinical settings. HSAPs contain a plethora of amino acids that encourage binding to the 
different materials. Traditionally, the amine and carboxylic acid groups of the albumin matrix are 
exploited for binding to hydrophilic molecules. However, there are some hydrophobic amino 
acid residues present that are capable of binding to inorganic QDs. There was inefficient loading 
of the QDs inside the HSAPs, and this could be overcome by a surface ligand exchange of the 
QDs. Replacing the TOPO capping ligand with a hydrophilic ligand such as 16-
mercaptohexadecanoic acid (MHDA) would make them water soluble and biocompatible. 
Loading would be much more efficient, however, assay sensitivity might not improve due to 
lower quantum yield and brightness of MHDA-capped QDs. The current assay was able to detect 
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50 pg/mL of IL-15 and 0.5 ng/mL of MCP-1. While this shows potential for albumin-based 
assay development, these detection limits are not better than currently available detection 
methods.  
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Chapter 5 
 
Multifunctional Human Serum Albumin Nanoparticles for Targeted Drug 
Release 
 
This chapter presents collaborative work with Dr. David Bwambok (Part I) and Connor Carry, 
James Liu, and Dr. Benjamin Lee of Tulane University School of Medicine (Part II). Images in 
Part II were reprinted by permission of John Wiley & Sons, Inc. © 2016 
5.1 Abstract 
 
Human serum albumin nanoparticles (HSAPs) were used for targeted drug release 
studies. HSAPs are monodisperse, stable, and biocompatible. These robust nanoparticles are 
capable of encapsulating various materials and can be functionalized for use in a multitude of 
therapeutic applications. HSAPs loaded with superparamagnetic iron oxide nanoparticles 
(SPIONs) and fluorescein-5-thiosemicarbazide were examined for their potential as drug release 
agents. An external magnetic field was applied to the nanocomposites to monitor the amount of 
fluorophore released upon exposure to the magnetic field. Increasing the strength of the magnetic 
field correlated to an increase in fluorescence intensity of the HSAPs supernatant. Dynamic light 
scattering (DLS) showed an overall decrease in particle size of the nanocomposites over time. 
Results indicate that magnetic HSAP nanoparticles may be excellent drug carriers with the 
ability to control release from the albumin matrix using an external magnetic field. 
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HSAPs were also used in conjunction with photothermal laser ablation to treat a renal cell 
carcinoma mouse model in vivo. Gold nanorods (AuNRs) and sorafenib (SRF), a tyrosine kinase 
inhibitor, were encapsulated into HSAP nanoparticles (HSA-AuNR-SRFs) and used for 
treatment of the tumors. The nanocomposites were injected into the tumor sites and examined for 
tumor necrosis. Injection of HSA-AuNR-SRFs alone and treatment with the laser alone showed 
minimal tumor shrinkage and low necrosis. The combination of laser ablation and HSA-AuNR-
SRFs resulted in 100% tumor necrosis and total elimination of any visible tumor after treatment. 
These results show great promise to utilize HSAPs as multimodal systems for theranostic 
treatment applications. 
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5.2 Introduction 
 
Efforts to use nanotechnology for targeted drug delivery in cancer treatment methods 
may revolutionize cancer therapies.
1
 Improvements in disease diagnosis, treatment, and 
prevention are all moving toward nanoscale systems.
2
 Controlled release of anticancer drugs 
from nanoparticle carriers has gained attention as a new method for targeted drug delivery. The 
most common and effective anticancer drugs tend to kill healthy cells as well as cancerous cells.
3
 
Nanocarriers are able to deliver anticancer drugs directly to a tumor site reducing the likelihood 
of affecting healthy cells.
2-3
 Presently, drug delivery systems are dominated by synthetic 
materials because there is precise control over synthesis and exploitation of their properties. 
Examples of common synthetic nanocarriers for targeted drug delivery include polymeric 
nanoconstructs, carbon nanotubes, and gold nanocages.
1, 4
 Natural materials such as lipids, 
nucleic acids, proteins, and peptides have been explored as more biocompatible alternates for 
nanocarrier development.
4
 Mechanisms of controlled release from nanocarriers have been 
reported through changes in different stimuli including pH, enzymes, temperature, and laser 
irradiation.
2, 4-6
 
Human serum albumin (HSA) is the most common protein in blood plasma, and it avoids 
rejection when used in vivo.
7
 Development of human serum albumin nanoparticles (HSAPs) as a 
natural material for targeted drug delivery has become a platform of interest.
8
 HSAPs are 
biodegradable, and naturally biocompatible for functionalization because of an abundance of 
charged amino acids.
7
 Their versatility allows them to encapsulate drugs and other 
nanomaterials.
9
 HSAPs are also easily bioconjugated for surface labeling of antibodies or other 
molecules through interactions primarily with the carboxylic acids and amines of the amino 
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acids.
10
 Controlled release studies using HSAPs for treatment of neuroblastomas and breast 
cancer cells show that HSA has great promise as an anticancer drug nanocarrier.
11
  
Magnetically-triggered release from nanocarriers utilizes an external magnetic field to 
stimulate magnetic nanoparticles which degrades the nanocarrier and releases the anticancer 
drug.
12
 Studies using magnetic fields to release drugs from magnetically labeled materials have 
shown potential for their use therapeutically.
13
 Using an external magnetic field improves their 
possibility as nanocarriers because drug release can be triggered non-invasively.
14
 Reports using 
magnetically labeled silica, collagen gels, polymersomes, and polymeric nanocomposites have 
shown release of fluorescent materials.
12
 Superparamagnetic iron oxide nanoparticles (SPIONs) 
are ideal for magnetically enabled nanocarriers. SPIONs range between 10 – 100 nm in diameter 
and are coated with biocompatible polymers that enable them for bioconjugation.
15
 Not only can 
they be used as drug delivery vehicles, but they can also be used to monitor materials via 
magnetic resonance imaging (MRI).
16
  
The main feature of the magnetic nanoparticles is their superparamagnetism. This 
property is due to their small size, and when an external magnetic field is applied, the 
nanoparticles become magnetized.
15
 When the magnetic field is removed there is no residual 
magnetization.
17
 Unlike larger magnets, SPIONS do not exhibit multiple domains.
18
 There is a 
uniform, single spin that has high magnetic susceptibility not seen in bulk magnets. SPIONs have 
a stronger and faster magnetic response with low remanence and nearly zero coercivity.
14
 These 
features make them excellent candidates for targeted drug delivery.
19
 SPIONs have already 
shown use in targeted hypothermia where cancer cells are treated by localized, internal heating.
20
 
When exposed to a high frequency magnetic field they become heated due to Neel and Brown 
relaxation.
14
 Encapsulating SPIONs in human serum albumin (HSA) can allow for efficient 
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cellular uptake and localization within tumor sites. Degrading the HSA matrix from external 
magnetic field application can effectively and precisely release an anticancer drug.
20
  
Gold nanorods (AuNRs) are another avenue through which multifunctional drug delivery 
HSA vehicles can be developed.
21
 They have been of interest as biosensors for disease diagnosis 
and monitoring. AuNRs absorb energy from near-infrared light and emit it as heat.
22
 This can 
directly destroy tumors without affecting nearby tissues.
23
 Encapsulation in HSAPs along with 
an anticancer drug forms an ultrasensitive nanomaterial capable of in vivo diagnostic 
applications.  Photothermal laser ablation therapy provides irradiation to the AuNR encapsulated 
HSAPs (HSAP-AuNRs) which effectively heats and destroys tumor cells.
24
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Part I: Magnetically Triggered Release of Fluorescent Drug Analog from Human 
Serum Albumin Nanoparticles 
5.3 Experimental Methods 
 
5.3.1 Materials and Reagents 
All chemicals were used as received without modification unless otherwise noted. Human 
serum albumin (HSA), lyophilized powder (≥ 97%), aqueous glutaraldehyde (8%), sodium 
hydroxide (≥97%), and fluorescein-5-thiosemicarbazide (80%) were purchased from Sigma-
Aldrich (St. Louis, MO). Polyethylene glycol (PEG) coated iron oxide magnetic nanoparticles 
(10 nm, 1 mg/mL) were purchased from Ocean Nanotech (San Diego, CA). Phosphate buffered 
saline (PBS) was obtained from Invitrogen (Waltham, MA). Ethanol, 200-proof, ACS/USP grade 
was purchased from Pharmco-AAPER (Brookfield, CT). Nanopure deionized and distilled water 
(18.2 MΩ) purified with a Barnstead Nanopure system was used for all experiments. 
5.3.2. Synthesis of Fluorescent and Magnetic Multifunctional Human Serum Albumin 
Nanoparticles 
Multifunctional human serum albumin nanoparticles loaded with a fluorescent drug 
analog and magnetic nanoparticles were prepared using a modified common desolvation 
method.
8, 25
 A stock solution of HSA was prepared by dissolving 100 mg of HSA into 1 mL of 
nanopure water. The pH was adjusted to 8.2 using 0.01 M NaOH. A 500 µL aliquot of the HSA 
stock solution was mixed with 200 µL of fluorescein-5-thiosemicarbazide (1 mg/mL), 30 µL of 
PEG-coated iron oxide nanoparticles (10 mg/mL) in water, and 270 µL of nanopure water. The 
mixture stirred for 2 hours at room temperature. Desolvation of the HSAPs solution began upon 
the addition of 3 mL of ethanol. The ethanol was added using a peristaltic pump at a rate of 1 
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mL/min. To begin the HSA crosslinking, 4.7 µL of 8% glutaraldehyde was added to the HSAP 
solution. After stirring for 24 hours, the HSAPs were centrifuged for 30 minutes at 13,000 rpm 
and washed with ethanol. The resulting fluorescent and magnetic HSAPs were resdispersed in 
PBS buffer via sonication and stored at 4 °C. 
5.3.3 Characterization of Fluorescent and Magnetic Multifunctional Human Serum 
Albumin Nanoparticles 
Average particle size, size distribution, zeta potential, and morphology of the HSAP 
nanoparticles were acquired using dynamic light scattering (DLS), scanning electron microscopy 
(SEM), and transmission electron microscopy (TEM). Field emission SEM (FESEM) images 
were taken using a LEO 1540VP (LEO Elektronemmikroskpie GmbH, Oberkochen, Germany) 
FESEM electron microscope. The HSAP nanoparticles were dried on a glass slide and sputter 
coated with gold. TEM images were taken using a JEOL 2010 TEM electron microscope. The 
samples were prepared by drop casting the HSAP nanoparticle solution onto a carbon coated 
copper grid and allowing it to air dry. The DLS used was a Desla S Nano system (Beckman 
Coulter Instruments). The HSAP nanoparticle solution was diluted with PBS buffer (pH 7.4) 
prior to analysis. A Superconducting Quantum Interference Device (SQUID) magnetometer was 
used to determine the magnetic properties of the HSAPs. The samples were isolated by 
centrifugation and air dried.  
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5.3.4 Magnetically-triggered Fluorophore Release from HSAPs  
To employ the magnetic nanoparticles for fluorophore release from the HSAPs, 150 µL 
of the HSAPs were placed in a glass container 3 mm in diameter. The sample was situated 
between a ferrite ring wrapped with a copper coil to provide an AC voltage. The maximum 
frequency was 28 kHz and the maximum field was 900 Oe. The HSAP nanoparticles were 
centrifuged for 10 minutes at 10,000g after exposure to the magnetic field and the supernatant 
was measured using a microplate reader (Molecular Devices, SpectraMax M2) to determine the 
amount of fluorophore released. The excitation and emission wavelengths used for the released 
fluorescein-5-thiosemicarbazide were 495 nm and 525 nm, respectively. An Olympus IX71 
inverted fluorescence microscope with a digital camera was used for imaging of the HSAP 
before and after exposure to the magnetic field. The Delsa Nano S system (Beckman Coulter 
Instruments) was used to monitor change in particle size of the HSAP after magnetic field 
exposure. HSAP nanoparticles were measured using DLS after magnetic field exposure for 0, 30, 
40, 45, and 55 minutes.  
5.4 Results and Discussion 
 
5.4.1 Characterization of Multifunctional Fluorescent and Magnetic Human Serum 
Albumin Nanoparticles 
Human serum albumin nanoparticles were loaded with a fluorescent drug analog and 
superparamagnetic iron oxide nanoparticles (SPIONs) to evaluate degradation of HSAPs and 
release of the fluorophore. HSAP nanoparticles are formed primarily by a desolvation process 
which has been repeatedly reported to be a robust and reproducible technique for synthesis. 
Ethanol is added to the HSA solution causing the albumin to precipitate followed by stabilization 
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of the protein nanoparticles with a glutaraldehyde crosslinker.
8, 25-26
 SEM imaging has shown 
that the resulting HSAP nanoparticles are uniform and spherical (Figure 5.1a). The TEM 
imaging clearly shows the magnetic nanoparticles embedded within the HSAP nanoparticles 
(Figure 5.1b); however, the high energy electron beam degrades or melts the protein during 
imaging. Using a lower voltage while cooling the sample stage with liquid nitrogen preserved the 
integrity of the HSAP nanoparticles and revealed the spherical nanoparticles consistent with the 
SEM imaging (Figure 5.1c). 
 
Figure 5.1 Electron microscopy images of multifunctional human serum albumin nanoparticles: 
(a) SEM image (10 kV), (b) TEM image (200 kV, room temperature), and (c) TEM image (80 
kV, -78 °C). 
DLS was used to measure particle size, zeta potential, and polydispersity of the HSAP 
nanoparticles. The average diameter of the nanoparticles was 158 ± 19 nm with a zeta potential 
of -48 mV. Zeta potential is a measure of electrostatic potential of a particle surface and is 
measured through electrophoretic mobility.
27
 It is a fundamental parameter of colloidal stability 
and can provide insight into particle dispersion or aggregation. The stability of a particle 
dispersion can be determined by the zeta potential, and typically, the larger the value whether 
positive or negative, the more stable the system. The polydispersity index (PDI) of the HSAP 
nanoparticles was 0.065 which indicates the nanoparticle solution is monodisperse. A perfectly 
uniform sample as determined by DLS has a PDI of 0.0, and a sample in the range 0.05-0.1 
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indicates a narrow, monodisperse system.
27
 These values demonstrate that the multifunctional 
fluorescent and magnetic HSAP nanoparticles are excellent candidates for targeted drug delivery 
applications.  
Table 5.1 Dynamic Light Scattering (DLS) data for HSAPs. 
Human Serum Albumin Nanoparticles Loaded with magnetic iron oxide nanoparticles and 
fluorescein-5-thiosemicarbazide 
Particle diameter (nm) 158 ± 19 
Polydispersity Index (PDI) 0.065 ± 0.010 
Zeta potential (mV) -48 
 
Paramagnetic materials are attracted to an external magnetic field.
18
 In the presence of a 
magnetic field, the materials form internal magnetic moments in the direction of the external 
magnetic field and produce a net positive magnetization.
15
 When a material is small enough 
(diameter between 3-50 nm) to change rotation under the influence of temperature it becomes 
superparamagnetic.
19, 28-29
 The rotational changes of superparamagnetic materials from the 
thermal energy cause them to flip the direction of magnetization.
15, 29
 The magnetic properties of 
the HSAP nanoparticles were measured using a SQUID magnetometer with a field sweep 
between -15000 to 15000 Oe. 
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Figure 5.2 Field dependent magnetization of HSAP nanoparticles. 
 
The magnetization curve of the magnetic HSAP nanoparticles does not have a hysteresis 
loop which is consistent with superparamagnetic nanoparticles (Figure 5.2).
30
 When a magnetic 
field is removed from a ferromagnetic material, it does not relax to zero magnetization unless a 
magnetic field of the opposite direction is applied.
14-15
 Applying alternate magnetic fields results 
in a retraceable hysteresis loop often referred to as the magnetic “memory” of a ferromagnetic 
material.
30
 The absence of a hysteresis loop indicates zero coercivity which is another prominent 
feature of superparamagnetic particles. Coercivity is a measure of the magnetic field strength 
needed to demagnetize a ferromagnetic material.
14, 30
 The superparamagnetic HSAP 
nanoparticles are enabled only in the presence of a magnetic field further presenting them as 
strong candidates for controlled drug delivery tools. 
5.4.2 Magnetized fluorophore release from multifunctional HSAP nanoparticles 
An applied magnetic field was applied to the HSAP nanoparticles to release fluorescein-
5-thisemicarbazide. The fluorophore acts as a fluorescent drug analog and gives insight in to how 
the HSAP nanoparticles might behave as drug delivery carriers.
31
 The HSAP nanoparticles in 
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PBS buffer were placed in a glass container situated between a ferrite ring wrapped with a 
copper coil. The nanoparticles were exposed to a maximum frequency of 28 kHz and the 
maximum field strength was 900 Oe. The particles were separated by centrifugation after 
exposure to the magnetic field, and the fluorescence intensity of the supernatant was measured to 
evaluate the amount of fluorophore released. An increase in the amount of fluorophore released 
directly correlated to an increase in magnetic field strength (Figure 5.3). This can provide a 
means for control of targeted drug release from the nanoparticles. 
 
Figure 5.3 Release of fluorescein-5-thiosemicarbazide from magnetic HSAP nanoparticles as a 
function of magnetic field strength. 
 
The duration of the magnetic field also plays a factor in the amount of fluorophore 
released from the nanoparticles. More fluorophore was released the longer the magnetic field 
was applied (Figure 5.4). The same magnitude was applied for each exposure time. A small 
amount of fluorescence was detected even without application of the magnetic field. This could 
be background fluorescence from fluorophore not entirely removed during the washing as well 
as some leakage from the HSAP nanoparticles over time. There was no fluorescence intensity 
increase from unloaded HSAP nanoparticles without iron oxide nanoparticles indicating the 
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observed fluorophore release resulted from the magnetic field. After 1 hour of exposure there 
was still some fluorophore that was not released indicating the magnetic field did not completely 
degrade the HSAP nanoparticle matrix.  
 
Figure 5.4 Release of fluorescein-5-thiosemicarbazide from magnetic HSAP nanoparticles as a 
function of time. 
 
Fluorescence microscopy images of the HSAP nanoparticles before and after magnetic-
triggered released were acquired (Figure 5.5). The resolving power of the fluorescence 
microscope is not high enough to visualize individual HSAP nanoparticles, however, aggregates 
are visible. Prior to exposure to the magnetic field (Figure 5.5a), groups of aggregates are 
noticeable, while after 10 and 30 minutes of magnetic field treatment, fewer aggregates are 
observed (Figures 5.5 b,c). The magnetic field exposure caused localized heating of the 
superparamagnetic iron oxide nanoparticles which is responsible for the breakdown of the 
albumin matrix over time. 
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Figure 5.5 Fluorescence microscopy images of the release of fluorescein-5-thiosemicarbazide 
after magnetic treatment for (a) 0 min, (b) 10 min, and (c) 30 min. 
 
The DLS results show that there is an overall decrease in size of the HSAP nanoparticles 
over time under r.f. magnetic field exposure (Figure 5.6). The PDI of the HSAP nanoparticles 
also increased over this time indicating that the nanoparticle system is no longer monodisperse. 
The change in polydispersity supports the nanoparticle degradation as a result of magnetic field 
treatment.  
 
Figure 5.6 Change in diameter of magnetic multifunctional HSAP nanoparticles over time after 
magnetic field treatment. 
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Part II: Treatment of Renal Cell Carcinoma with Multifunctional Gold Nanorod 
Human Serum Albumin Nanoparticles 
5.6 Experimental Methods 
 
5.6.1 Materials and Reagents 
All chemicals were used as received without modification unless otherwise noted. Human 
serum albumin (HSA), lyophilized powder (≥ 97%) and aqueous glutaraldehyde (8%), were 
purchased from Sigma-Aldrich (St. Louis, MO). Phosphate buffered saline (PBS) was obtained 
from Invitrogen (Waltham, MA). Ethanol, 200-proof, ACS/USP grade was purchased from 
Pharmco-AAPER (Brookfield, CT). Bare gold nanorods (AuNRs) were purchased from 
Nanopartz Inc. (Loveland, CO). Sorafenib (SRF) was supplied by Tulane University Medical 
Center. Nanopure deionized and distilled water (18.2 MΩ) purified with a Barnstead Nanopure 
system was used for all experiments. 
5.6.2 Synthesis of HSAP, HSAP-AuNR, HSAP-AuNR-SRF Nanoparticles 
 The HSAP-AuNR-SRFs were prepared similarly to the magnetic HSAPs via ethanolic 
desolvation.
24, 32
 For unloaded, empty HSAPs, 1 mL of water was added to a 20 µL aliquot of the 
HSA stock solution. HSAP-AuNRs were prepared by adding of 1 mL of AuNR stock solution 
(5.9 x 10
11
 AuNRs) to a 20 µL aliquot of the HSA stock solution. HSAPs containing both 
AuNRs and a tyrosine kinase inhibitor (TKI) were prepared by adding sorafenib (SRF) in 
addition to the 1 mL AuNR stock solution. A 0.5 mL aliquot of SRF stock solution (1 mg/mL 
DMSO/EtOH) was added dropwise at a rate of 1 mL/min. To all samples, 3 mL of 100% ethanol 
was added at 1 mL/min using a peristaltic pump to initiate desolvation. Crosslinking of the 
HSAP samples was initiated by the addition of 4.7 µL of 8% glutaraldehyde. The nanoparticle 
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solutions were stirred for 24 hours followed by centrifugation for 30 minutes at 13,000 rpm and 
washing using a 1:3 water/EtOH solution. The samples were resuspended in nanopure water via 
ultrasonication using a F60 Sonic Dismembrator (Fisher Scientific, Pittsburgh, PA) at 2 W root 
mean square. The resulting HSAP samples were stored in nanopure water at 4 °C prior to use. 
5.6.3 Photothermal Laser Ablation Therapy Using HSA-AuNR-SRF Nanoparticles 
Foxn1
nu
 athymic nude mice were subcutaneously injected with a 200 µL solution 
containing a 1:1 ratio of 100 µL of RCC 786-0 cells (2.5 x 10
6
 cells) and 100 µL of Matrigel 
basement membrane matrix. Each mouse grew bilateral tumors, one as a control, and the other 
for treatment. Once the tumors reached 1 cm in their longest direction, treatment with HSA-
AuNR-SRF nanoparticles began. The tumors were injected with 0.1 mL SRF 10 mM SRF 
solution in PBS, 0.1 mL suspension of HSA-AuNR stock or 0.1 mL HSA-AuNR-SRF stock. 
Cellular uptake of the particles occurred over 24 h. Laser ablation was performed using a 
Laserglow Technology collimated diode laser system (Toronto, Canada) for continuous wave 
irradiation at 2100 mW and 808 nm. The laser was placed 14 cm directly above the tumor, 
covering an area 1 cm in diameter and applied for 6 min. The tumors were harvested and 
haematoxylin and eosin (H&E) slides were prepared for examination. 
5.7 Results and Discussion 
 
5.7.1 Characterization of Human Serum Albumin Nanoparticles Loaded with Gold 
Nanorods and a Tyrosine Kinase Inhibitor 
The desolvation technique for human serum albumin nanoparticle synthesis was also 
used to encapsulate AuNRs and sorafenib (SRF), a tyrosine kinase inhibitor (TKI) approved for 
renal cell carcinoma treatment. The HSAP nanoparticles containing AuNRs and SRF (HSA-
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AuNR-TKI) coupled with photothermal ablation were used to assess treatment in a renal cell 
carcinoma (RCC) mouse model. The human serum albumin nanocomposites were synthesized in 
a similar manner as those loaded with iron oxide and fluorescein-5-thiosemicarbazide. To a stock 
solution of HSA (100 mg/mL), AuNR was added to form HSA-AuNR nanocomposites. AuNR 
and SRF were added to the HSA stock solution to form the HSA-AuNR-TKI nanocomposites. 
Ethanol was added for denaturation and to initiate aggregation. Gluteraldehyde was then added 
for crosslinking of the amine groups on the albumin. After stirring overnight, the HSAPs were 
washed and purified via centrifugation and ultasonication. The resulting HSAPs were 
resdispersed in nanopure water. Spherical HSA-AuNR-TKI nanoparticles were imaged using 
TEM (Figure 5.7). The AuNRs are clearly encapsulated within the HSA nanoparticles. There 
was some melding of the nanoparticles due to heat from the high energy electron beam.  
 
Figure 5.7 TEM image of HSA-AuNR-TKI nanoparticle.  
5.7.2 Renal Cell Carcinoma Tumor Treatment Using HSA-AuNR-TKIs with Laser 
Ablation 
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Human metastatic RCC cell line RCC 786-0 cells were cultured and injected into Foxn1
nu
 
athymic nude mice subcutaneously for in vivo tumor establishment. Treatment with HSA 
nanoparticles commenced once the tumor size reached 1 cm in the longest direction. Each mouse 
grew bilateral tumors: one for treatment and one as a control. Marked tumors were injected with 
10 mM SRF, HSA-AnNR stock, or HSA-AuNR-TKI stock solutions. After 24 hours of cellular 
uptake, the tumors were treated with laser ablation (~2100 mW at λ = 808 nm) using a 
collimated diode laser system. The control and treated tumors were harvested and used to create 
haematoxylin and eosin (H&E) slides, and they were also silver stained for imaging.  
 
Figure 5.8 Percentage of tumor necrosis and average tumor size after treatment. 
The average tumor size of the controls was 9.38 mm with 1% tumor necrosis. Tumors 
treated with SRF and HSA-SRF without laser ablation showed no statistical difference in tumor 
necrosis with 4.2% and 11%, respectively. There was also only a slight decrease in tumor size 
with 9.2 mm and 8.25 mm after treatment. Utilizing laser ablation alone and with HSA-AuNR 
nanoparticles exhibited 62% and 63.4% tumor necrosis, respectively as well as an average tumor 
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size of 3.9 mm and 12.2mm. Combining laser ablation with HSA-AuNR-SRF resulted in 100% 
tumor necrosis and <0.01 mm average tumor size (Figure 5.8).  
Figure 5.9 Histological samples of tumor after treatment: (a) control with viable tumor structure, 
(b) tumor after treatment with SRF, (c) tumor after treatment with HSA-AuNR-TKI, (d) laser 
treatment alone, (e) 20x image of HSA-AuNR tissue with silver staining showing AuNRs, and 
(f) tumor after treatment with laser irradiation and HSA-AuNR-TKI showing no viable tumor 
 
Histological tissue samples show how each treatment type affected tumor viability 
(Figure 5.9). The control tumor without any treatment displayed viable tumor structure as 
indicated by the H&E staining throughout the tissue. Tissue samples after treatment with SRF 
alone or HSA-AuNR-SRFs alone presented mild coagulative necrosis. Using laser ablation 
photothermal therapy alone resulted in major coagulative necrotic tissue. The AuNRs are visible 
in the histology tissue samples after magnification and silver staining. Combining laser 
irradiation and HSA-AuNR-SRFs showed no viable tumor visible in the histological tissues 
which is consistent with the total shrinkage in tumor size. 
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5.8 Conclusions 
 
 Multifunctional HSAPs encapsulated with superparamagnetic iron oxide nanoparticles or 
gold nanrods were explored for targeted drug delivery. The HSAPs were successfully prepared 
through simple desolvation and crosslinking with glutaraldehyde. HSAPs have been shown to be 
versatile and non-invasive nanocarriers. Their broad functionality enables them to be useful in 
chemotherapeutic applications. New drug therapies can utilize the effectiveness and robustness 
of HSAPs. Exposure to an external magnetic field or laser ablation photothermal therapy creates 
a direct and controlled environment for drug release minimizing effects to neighboring healthy 
cells. 
 Fluorescence microscopy and DLS analysis revealed that the applied magnetic field 
caused the HSAPs to degrade and release the fluorescent drug analog. The amount of 
fluorophore release was dependent on the strength of the magnetic field as well as on the 
duration of exposure. Combining magnetically trigged release with an anticancer drug could 
result in significant cell death as seen through laser irradiation.  Laser irradiation of HSA-AuNRs 
has been shown to promote NIR-induced hyperthermia. Total cell death and complete 
elimination of tumor sites was achieved solely by the combination therapy of laser irradiation 
with the HSA-AuNR-TKI nanoparticles.  Both methods demonstrate that human serum albumin 
nanoparticles are excellent and ideal tools for controlled release of anticancer drugs as well as for 
drug delivery vehicles.  
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Chapter 6 
 
Summary and Conclusions 
 
 Luminescent semiconductor nanocrystals or quantum dots (QDs) have demonstrated 
amazing potential for use in biological and bioanalytical applications.
1
 They possess unique 
optical and photophysical properties that give them tremendous advantages over conventional 
fluorescent organic dyes. CdSe/ZnS QDs are currently the most commonly used QDs for 
biosensing applications because of their exceptional tunability and brightness.
2-3
 CdSe/ZnS are 
tunable through the UV-Vis-NIR spectrum enabling them to be useful in the largest range of 
applications.
4-5
 Some of these properties include: broad absorption spectra, narrow emission 
spectra, a large Stokes shift, and a large molar extinction coefficient.
6
 They also exhibit excellent 
photostability, high quantum yield, high chemical stability, and size-dependent luminescence.
7-8
 
This work primarily focused on utilizing QDs in multiplex immunoassays. The size dependent 
luminescence, broad absorption spectra, and narrow emission are responsible for the distinctive 
multiplexing feature.
9-10
 Multiple analytes can be detected simultaneously using one excitation 
light source. QDs of different sizes and fluorescence emission wavelengths can be excited 
together and produce narrow emission peaks allowing the different analytes to be distinguished 
from one another.
11-12
 
 A key feature of immunoassay development is the specificity of the detection probe.
13
 
Developing an appropriate bioconjugate for use as the detection probe is fundamental to 
immunoassay optimization.
14
 The first project focused on enabling CdSe/ZnS QDs to be 
biocompatible with biological buffers commonly used in assays yet retain their inherent 
brightness and high quantum yield. Encapsulating QDs into mesoporous silica facilitated 
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bioconjugation while preserving the unique properties of CdSe/ZnS. The QDs remained stable in 
the mesoporous silica particles due to strong hydrophobic interactions between a C18 chain and 
TOPO capping ligand on the surface of the QDs.
2, 15
 The quantum dot silica composite particles 
(SiQDs) were further modified with thiol (-SH) and amine (-NH2) groups through (3-
mercaptopropyl)trimethoxysilane (MPTMS) and (3-aminopropyl)triethoxysilane (APTES), 
respectively. Addition of the silanes enables bioconjugation for coupling with antibodies. The 
bioconjugates are formed through the use of a crosslinking agent. Sulfosuccinimidyl 4-(N-
maleimidomethyl)cyclohexnane-1-carboxylate (sulfo-SMCC) and ethylene 
glycolbis(succinimidyl succinate) (EGS) were used to crosslink the thiol and amine groups, 
respectively. Addition of the amine group on the surface of the SiQDs creates an overall net 
positive charge on the surface and enables water solubility. To promote water solubility of the 
thiol modified SiQDs, (trimethoxysilylpropyl) ethylenediamine triacetic acid (TMS-EDTA) was 
added to the surface as well.  
 These bioconjugates were utilized in a quantum dot based fluorescence immunoassay to 
detect atherosclerosis biomarkers IL-15 and MCP-1. Direct detection assays were compared with 
sandwich detection assays, and using a sandwich detection immunoassay significantly increased 
detection limits of the biomarkers. In a sandwich immunoassay, a capture antibody is 
immobilized on the surface of a well plate. The well plate is activated with maleic anhydride 
groups, which readily bind to antibodies. The antigen is added to the well to bind to the capture 
antibodies. The presence of the capture antibody pulls down more antigens and provides specific 
binding sites rather than the nonspecific adsorption that occurs in a direct detection assay. The 
quantum dot-antibody bioconjugates are added to the well for binding to the antigen. Biomarker 
presence is quantified by measuring the fluorescence of the quantum dots present on the well 
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plate. Fluorescence intensity correlates to the amount of antigen present. The detection limits of 
this immunoassay were 1 pg/mL for IL-15 and 50 pg/mL for MCP-1, which is an improvement 
from currently, reported detection methods.  
 The focus of this dissertation shifted to exploration of human serum albumin 
nanoparticles (HSAPs). Human serum albumin (HSA) is the most abundant protein in blood 
plasma, and it is extremely versatile and capable of being utilized in numerous biological 
applications.
16-17
 HSAPs can freely transport throughout the body and they are excellent 
candidates as drug nanocarriers.
18
 The binding properties of HSAPs allow them to encapsulate 
various substances including insoluble chemotherapeutic drugs.
19-20
 They can transport these 
drugs directly to a tumor site and spare neighboring healthy cells exposure to toxicity.
21
 HSAPs 
are also multimodal: they can transport materials and they can non-invasively control the release 
of a given substance. Their multifunctionality enables them useful for assessment and treatment 
purposes, and they can also track and monitor drug release.  
 Quantum dot loading of HSAPs was examined to explore their use in an immunoassay. 
QDs were loaded into HSAPs via desolvation and crosslinking, but the loading was inefficient, 
and further studies are required to enhance loading of QDs into HSAPs. The HSAP-QD-antibody 
bioconjugates was able to detect IL-15 and MCP-1; however, distinguishing between the two 
biomarkers during multiplexing was not achieved.  
 The last two projects reported were collaborative efforts examining HSAPs for targeted 
drug delivery applications. First, HSAPs were loaded with superparamagnetic iron oxide 
nanoparticles and fluorescein-5-thiosemicarbazide as a fluorescent drug analog. A magnetic field 
was applied to the HSAPs to learn how the fluorophore was released upon albumin degradation 
as this could give insight on how drug molecules are released from HSAPs. Only in the presence 
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of the magnetic field was the fluorescein dye released from the albumin matrix. The controlled 
release potential of HSAPs was directly observed magnetically. And secondly, gold nanorods 
and a tyrosine kinase inhibitor (Sorafenib) were loaded in to HSAPs for treatment of a renal cell 
carcinoma mouse model. The HSAPs were injected directly into tumor sites, and the gold 
nanorods were activated by laser irradiaton. This allows direct control of the breakdown of the 
HSAPs to release the drug into tumor. Laser ablation causes the gold nanorods to heat up 
resulting in hyperthermia.
22-23
 As the integrity of the HSAPs degrade, the drugs inside are 
released to the tumor site. Utilizing both Sorafenib and the gold nanorods together in the mouse 
model resulted in 100% tumor necrosis with no viable tumor present.
24
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